Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

<!DOCTYPE html> <html lang="en" > <head > <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="HandheldFriendly" content="True" /> <meta name="MobileOptimized" content="320" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <link rel="stylesheet" href="/static/assets/style-70b9163a.css" /> <script type="module" crossorigin="" src="/static/assets/base_style-ec2bc71e.js"></script> <link rel="stylesheet" href="/static/assets/style-ef962842.css" /> <link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" /> <script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script> <style> @media screen and (min-width: 64em) { div.pmc-wm { background: repeat-y; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E"); padding-left: 3rem; } } </style> <link rel="apple-touch-icon" sizes="180x180" href="/static/img/favicons/apple-touch-icon.png" /> <link rel="icon" type="image/png" sizes="48x48" href="/static/img/favicons/favicon-48x48.png" /> <link rel="icon" type="image/png" sizes="32x32" href="/static/img/favicons/favicon-32x32.png" /> <link rel="icon" type="image/png" sizes="16x16" href="/static/img/favicons/favicon-16x16.png" /> <link rel="manifest" href="/static/img/favicons/site.webmanifest" /> <link rel="mask-icon" href="/static/img/favicons/safari-pinned-tab.svg" color="#0071bc" /> <meta name="msapplication-config" content="/static/img/favicons/browserconfig.xml" /> <meta name="theme-color" content="#ffffff" /> <title> Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer - PMC </title>  <meta name="ncbi_app" content="cloudpmc-viewer" /> <meta name="ncbi_db" content="pmc" /> <meta name="ncbi_phid" content="6E4B40A474E04B730940A4000D5B7CDC.m_1" />  <meta name="ncbi_pdid" content="article" /> <link rel="preconnect" href="https://www.google-analytics.com" /> <link rel="dns-prefetch" href="https://cdn.ncbi.nlm.nih.gov" /> <link rel="preconnect" href="https://code.jquery.com" /> <meta name="ncbi_domain" content="jco"> <meta name="ncbi_type" content="fulltext"> <meta name="ncbi_pcid" content="journal"> <link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/"> <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"> <meta name="citation_journal_title" content="Journal of Clinical Oncology"> <meta name="citation_title" content="Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer"> <meta name="citation_author" content="Scott Gettinger"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Naiyer A Rizvi"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Laura Q Chow"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Hossein Borghaei"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Julie Brahmer"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Neal Ready"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="David E Gerber"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Frances A Shepherd"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Scott Antonia"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Jonathan W Goldman"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Rosalyn A Juergens"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Scott A Laurie"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Faith E Nathan"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Yun Shen"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Christopher T Harbison"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_author" content="Matthew D Hellmann"> <meta name="citation_author_institution" content="Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ."> <meta name="citation_publication_date" content="2016 Jun 27"> <meta name="citation_volume" content="34"> <meta name="citation_issue" content="25"> <meta name="citation_firstpage" content="2980"> <meta name="citation_doi" content="10.1200/JCO.2016.66.9929"> <meta name="citation_pmid" content="27354485"> <meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/"> <meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/"> <meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/pdf/JCO.2016.66.9929.pdf"> <meta name="description" content="Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced ..."> <meta name="og:title" content="Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer"> <meta name="og:type" content="article"> <meta name="og:site_name" content="PubMed Central (PMC)"> <meta name="og:description" content="Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced ..."> <meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/"> <meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@ncbi"> </head> <body > <a class="usa-skipnav " href="#main-content"> Skip to main content </a> <section class="usa-banner " aria-label="Official website of the United States government" > <div class="usa-accordion"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="grid-col-auto"> <img aria-hidden="true" class="usa-banner__header-flag" src="/static/img/us_flag.svg" alt="" /> </div> <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true"> <p class="usa-banner__header-text"> An official website of the United States government </p> <span class="usa-banner__header-action">Here's how you know</span> </div> <button type="button" class="usa-accordion__button usa-banner__button " aria-expanded="false" aria-controls="gov-banner-default" data-testid="storybook-django-banner" > <span class="usa-banner__button-text">Here's how you know</span> </button> </div> </header> <div class="usa-banner__content usa-accordion__content" id="gov-banner-default" hidden> <div class="grid-row grid-gap-lg"> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-dot-gov.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Official websites use .gov</strong> <br /> A <strong>.gov</strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-https.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Secure .gov websites use HTTPS</strong> <br /> A <strong>lock</strong> ( <span class="icon-lock"> <svg xmlns="http://www.w3.org/2000/svg" width="52" height="64" viewBox="0 0 52 64" class="usa-banner__lock-image" role="graphics-symbol" aria-labelledby="banner-lock-description" focusable="false"> <title id="banner-lock-title">Lock</title> <desc id="banner-lock-description"> Locked padlock icon </desc> <path fill="#000000" fill-rule="evenodd" d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" /> </svg> </span>) or <strong>https://</strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class="usa-overlay"> </div> <header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header > <div class="ncbi-header"> <div class="ncbi-header__container"> <a class="ncbi-header__logo-container" href="/"> <img alt=" PMC home page " class="ncbi-header__logo-image" src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" /> </a>  <button type="button" class="usa-menu-btn ncbi-header__hamburger-button " aria-label="Show menu" data-testid="navMenuButton" > <svg aria-hidden="true" class="ncbi-hamburger-icon" fill="none" focusable="false" height="21" viewBox="0 0 31 21" width="31" xmlns="http://www.w3.org/2000/svg"> <path clip-rule="evenodd" d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z" fill="#F1F1F1" fill-rule="evenodd" /> </svg> </button>  <div class="ncbi-header__desktop-buttons">  <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button " aria-expanded="false" aria-controls="search-field-desktop-navigation" aria-label="Show search overlay" data-testid="toggleSearchPanelButton" data-toggle-search-panel-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#search" /> </svg> Search </button>  <div class="ncbi-header__login-dropdown"> <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button " aria-expanded="false" aria-controls="login-dropdown-menu" aria-label="Show login menu" data-testid="toggleLoginMenuDropdown" data-desktop-login-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#person" /> </svg> <span data-login-dropdown-text>Log in</span>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow> <use xlink:href="/static/img/sprite.svg#expand_less" /> </svg>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow> <use xlink:href="/static/img/sprite.svg#expand_more" /> </svg> </button>  <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu" id="login-dropdown-menu" data-desktop-login-menu-dropdown hidden> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> <li class="usa-nav__submenu-item"> <button type="button" class="usa-button usa-button--outline ncbi-header__login-dropdown-logout-button " data-testid="desktopLogoutButton" data-desktop-logout-button > Log out </button> </li> </ul> </div> </div> </div> </div>  <div class="ncbi-search-panel ncbi--show-only-at-desktop" data-testid="searchPanel" data-header-search-panel hidden> <div class="ncbi-search-panel__container"> <form action="https://www.ncbi.nlm.nih.gov/search/all/" aria-describedby="search-field-desktop-navigation-help-text" autocomplete="off" class="usa-search usa-search--big ncbi-search-panel__form" data-testid="form" method="GET" role="search"> <label class="usa-sr-only" data-testid="label" for="search-field-desktop-navigation"> Search… </label> <input class="usa-input" data-testid="textInput" id="search-field-desktop-navigation" name="term" placeholder="Search NCBI" type="search" value="" /> <button type="submit" class="usa-button " data-testid="button" > <span class="usa-search__submit-text"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="usa-nav"> <p class="usa-sr-only" id="primary-navigation-sr-only-title"> Primary site navigation </p>  <button type="button" class="usa-nav__close ncbi-nav__close-button " aria-label="Close navigation menu" data-testid="navCloseButton" > <img src="/static/img/usa-icons/close.svg" alt="Close" /> </button>  <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6" role="search"> <label class="usa-sr-only" for="search-field"> Search </label> <input class="usa-input" id="search-field-mobile-navigation" type="search" placeholder="Search NCBI" name="search" /> <button type="submit" class="usa-button " >  <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==" class="usa-search__submit-icon" alt="Search" /> </button> </form>   <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop" data-mobile-login-menu hidden> <p class="ncbi-nav__mobile-login-menu-status"> Logged in as: <strong class="ncbi-nav__mobile-login-menu-email" data-mobile-login-email-text></strong> </p> <ul class="usa-nav__primary usa-accordion"> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> </ul> </div> <button type="button" class="usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop " data-testid="mobileLoginButton" data-mobile-login-button > Log in </button> </nav> </header> <section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box"> <div class="pmc-nav-container"> <div class="pmc-header__bar"> <div class="pmc-header__logo"> <a href="/" title="Home" aria-label="PMC Home"></a> </div> <button type="button" class="usa-button usa-button--unstyled pmc-header__search__button" aria-label="Open search" data-ga-category="search" data-ga-action="PMC" data-ga-label="pmc_search_panel_mobile" > <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#search"></use> </svg> <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="pmc-header__search"> <form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search"> <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label> <span class="autoComplete_wrapper flex-1"> <input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="/search/autocomplete/"/> </span> <button class="usa-button" type="submit" formaction="https://www.ncbi.nlm.nih.gov/pmc/" data-ga-category="search" data-ga-action="PMC" data-ga-label="PMC_search_button" > <span class="usa-search__submit-text">Search in PMC</span> <img src="/static/img/usa-icons-bg/search--white.svg" class="usa-search__submit-icon" alt="Search" /> </button> </form> <ul class="pmc-header__search__menu"> <li> <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search"> Advanced Search </a> </li> <li> <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list"> Journal List </a> </li> <li> <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link" data-ga-label="user guide"> User Guide </a> </li> </ul> </div> </div> </section> <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="5569692"> <div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary"> <div class="grid-row"> <div class="grid-col-fill display-flex"> <div class="display-flex"> <ul class="usa-list usa-list--unstyled usa-list--horizontal"> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open resources" data-extra-class="is-visible-resources" data-ga-category="resources_accordion" data-ga-action="click" data-ga-label="mobile_icon" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#more_vert"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <a href="https://doi.org/10.1200/JCO.2016.66.9929" class="usa-link display-flex" role="button" target="_blank" rel="noreferrer noopener" aria-label="View on publisher site" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#launch"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <a href="pdf/JCO.2016.66.9929.pdf" class="usa-link display-flex" role="button" aria-label="Download PDF" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button class="usa-button usa-button--unstyled collections-dialog-trigger collections-button display-flex collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_mobile" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC5569692%2F%23open-collections-dialog" data-in-collections="false" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button role="button" class="usa-button usa-button--unstyled citation-dialog-trigger display-flex" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_mobile" data-all-citations-url="/resources/citations/5569692/" data-citation-style="nlm" data-download-format-link="/resources/citations/5569692/export/" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> </button> </li> <li class="pmc-permalink display-flex"> <button type="button" class="usa-button usa-button--unstyled display-flex" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </div> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open article navigation" data-extra-class="is-visible-in-page" data-ga-category="actions" data-ga-action="open" data-ga-label="article_nav_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#list"></use> </svg> </button> </div> </div> </div> <div class="grid-container desktop:padding-left-6"> <div id="article-container" class="grid-row grid-gap"> <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content"> <div class="grid-container padding-left-0 padding-right-0"> <div class="grid-row desktop:margin-left-neg-6"> <div class="grid-col-12"> <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.<br/> Learn more: <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a> | <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/"> PMC Copyright Notice </a> </div> </div> </div> <div class="grid-row pmc-wm desktop:margin-left-neg-6">  <main id="main-content" class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0" > <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jco.png" alt="Journal of Clinical Oncology logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Clinical Oncology" title="Link to Journal of Clinical Oncology" shape="default" href="http://jco.ascopubs.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div> <div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Clin Oncol</button></div>. 2016 Jun 27;34(25):2980–2987. doi: <a href="https://doi.org/10.1200/JCO.2016.66.9929" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1200/JCO.2016.66.9929</a> </div> <nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu"> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li> <li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Clin%20Oncol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Clin%20Oncol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li> <li role="presentation"><a href="?term=%22J%20Clin%20Oncol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li> </ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs"> <hgroup><h1>Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer</h1></hgroup><div class="cg p"> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gettinger%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Scott Gettinger</span></a><div hidden="hidden" id="id1"> <h3><span class="name western">Scott Gettinger</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gettinger%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott Gettinger</span></a> </div> </div> <sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rizvi%20NA%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Naiyer A Rizvi</span></a><div hidden="hidden" id="id2"> <h3><span class="name western">Naiyer A Rizvi</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rizvi%20NA%22%5BAuthor%5D" class="usa-link"><span class="name western">Naiyer A Rizvi</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chow%20LQ%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Laura Q Chow</span></a><div hidden="hidden" id="id3"> <h3><span class="name western">Laura Q Chow</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chow%20LQ%22%5BAuthor%5D" class="usa-link"><span class="name western">Laura Q Chow</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borghaei%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Hossein Borghaei</span></a><div hidden="hidden" id="id4"> <h3><span class="name western">Hossein Borghaei</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Borghaei%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hossein Borghaei</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brahmer%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Julie Brahmer</span></a><div hidden="hidden" id="id5"> <h3><span class="name western">Julie Brahmer</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Brahmer%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Julie Brahmer</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ready%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Neal Ready</span></a><div hidden="hidden" id="id6"> <h3><span class="name western">Neal Ready</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ready%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Neal Ready</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gerber%20DE%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">David E Gerber</span></a><div hidden="hidden" id="id7"> <h3><span class="name western">David E Gerber</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gerber%20DE%22%5BAuthor%5D" class="usa-link"><span class="name western">David E Gerber</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shepherd%20FA%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Frances A Shepherd</span></a><div hidden="hidden" id="id8"> <h3><span class="name western">Frances A Shepherd</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shepherd%20FA%22%5BAuthor%5D" class="usa-link"><span class="name western">Frances A Shepherd</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Antonia%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Scott Antonia</span></a><div hidden="hidden" id="id9"> <h3><span class="name western">Scott Antonia</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Antonia%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott Antonia</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Goldman%20JW%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Jonathan W Goldman</span></a><div hidden="hidden" id="id10"> <h3><span class="name western">Jonathan W Goldman</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Goldman%20JW%22%5BAuthor%5D" class="usa-link"><span class="name western">Jonathan W Goldman</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Juergens%20RA%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Rosalyn A Juergens</span></a><div hidden="hidden" id="id11"> <h3><span class="name western">Rosalyn A Juergens</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Juergens%20RA%22%5BAuthor%5D" class="usa-link"><span class="name western">Rosalyn A Juergens</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Laurie%20SA%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Scott A Laurie</span></a><div hidden="hidden" id="id12"> <h3><span class="name western">Scott A Laurie</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Laurie%20SA%22%5BAuthor%5D" class="usa-link"><span class="name western">Scott A Laurie</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nathan%20FE%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Faith E Nathan</span></a><div hidden="hidden" id="id13"> <h3><span class="name western">Faith E Nathan</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nathan%20FE%22%5BAuthor%5D" class="usa-link"><span class="name western">Faith E Nathan</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Yun Shen</span></a><div hidden="hidden" id="id14"> <h3><span class="name western">Yun Shen</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yun Shen</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harbison%20CT%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Christopher T Harbison</span></a><div hidden="hidden" id="id15"> <h3><span class="name western">Christopher T Harbison</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harbison%20CT%22%5BAuthor%5D" class="usa-link"><span class="name western">Christopher T Harbison</span></a> </div> </div> <sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hellmann%20MD%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Matthew D Hellmann</span></a><div hidden="hidden" id="id16"> <h3><span class="name western">Matthew D Hellmann</span></h3> <div class="p"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hellmann%20MD%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthew D Hellmann</span></a> </div> </div> <sup>1</sup> </div> <ul class="d-buttons inline-list"> <li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li> <li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li> <li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li> </ul> <div class="d-panels font-secondary-light"> <div id="aip_a" class="d-panel p" style="display: none"> <div class="p" id="aff1"> <sup>1</sup>Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.</div> <div class="author-notes p"><div class="fn" id="cor1"> <sup>✉</sup><p class="display-inline">Corresponding author: Scott Gettinger, MD, Yale Cancer Center, 333 Cedar St, FMP127, New Haven, CT 06520; e-mail: <span>scott.gettinger@yale.edu</span>.</p> </div></div> </div> <div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Issue date 2016 Sep 1.</p></section></div></div> <div id="clp_a" class="d-panel p" style="display: none"> <div>© 2016 by American Society of Clinical Oncology</div> <div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div> </div> </div> <div>PMCID: PMC5569692 PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/27354485/" class="usa-link">27354485</a> </div> <div class="ra xbox p" role="complementary" aria-label="Related or updated information about this article"><div>See "<a href="https://pubmed.ncbi.nlm.nih.gov/27382094/" class="usa-link">Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer.</a>" on page 2953.</div></div> </div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2> <section id="sec1"><h3 class="pmc_sec_title">Purpose</h3> <p>Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non–small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3> <p>Fifty-two patients received nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity; postprogression treatment was permitted per protocol. The primary objective was to assess safety; secondary objectives included objective response rate (ORR) and 24-week progression-free survival (PFS) rate; overall survival (OS) was an exploratory end point.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3> <p>Any-grade treatment-related adverse events (AEs) occurred in 71% of patients, most commonly: fatigue (29%), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%). Ten patients (19%) reported grade 3 to 4 treatment-related AEs; grade 3 rash was the only grade 3 to 4 event occurring in more than one patient (n = 2; 4%). Six patients (12%) discontinued because of a treatment-related AE. The confirmed ORR was 23% (12 of 52), including four ongoing complete responses. Nine of 12 responses (75%) occurred by first tumor assessment (week 11); eight (67%) were ongoing (range, 5.3+ to 25.8+ months) at the time of data lock. ORR was 28% (nine of 32) in patients with any degree of tumor PD–ligand 1 expression and 14% (two of 14) in patients with no PD–ligand 1 expression. Median PFS was 3.6 months, and the 24-week PFS rate was 41% (95% CI, 27 to 54). Median OS was 19.4 months, and the 1-year and 18-month OS rates were 73% (95% CI, 59 to 83) and 57% (95% CI, 42 to 70), respectively.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3> <p>First-line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC.</p></section></section><section id="s1"><h2 class="pmc_sec_title">INTRODUCTION</h2> <p>Platinum-based doublet chemotherapy (PT-DC) is the current standard of care as first-line treatment of patients with advanced non–small-cell lung cancer (NSCLC) not driven by an epidermal growth factor receptor (<em>EGFR</em>) mutation or anaplastic lymphoma kinase (<em>ALK</em>) rearrangement, with objective response rates (ORRs) of 15% to 32%, median progression-free survival (PFS) and overall survival (OS) of 4.0 to 5.1 and 8.1 to 10.3 months, respectively, and 1- and 2-year OS rates of 30% to 44% and 10% to 18.9%, respectively.<sup><a href="#B1" class="usa-link" aria-describedby="B1">1</a>-<a href="#B6" class="usa-link" aria-describedby="B6">6</a></sup> Addition of bevacizumab to first-line PT-DC modestly improves clinical outcome versus chemotherapy alone in patients with nonsquamous NSCLC (ORR, 33% to 35%; median OS, 12.3 to 13.4 months; and 1-year OS rate, 51% to 54.1%).<sup><a href="#B3" class="usa-link" aria-describedby="B3">3</a>,<a href="#B7" class="usa-link" aria-describedby="B7">7</a></sup> In the small subset of patients with advanced NSCLC driven by <em>EGFR</em> or <em>ALK</em> genomic alterations, first-line therapy with EGFR or ALK tyrosine kinase inhibitors (TKIs), respectively, has consistently demonstrated higher ORRs (56% to 83%) and longer PFS (median, 9.2 to 13.1 months) with less toxicity than first-line PT-DC.<sup><a href="#B8" class="usa-link" aria-describedby="B8">8</a>-<a href="#B13" class="usa-link" aria-describedby="B13">13</a></sup></p> <p>Immune checkpoint inhibitors represent a distinct approach to treating malignancies, with durable antitumor activity and the potential for long-term survival demonstrated in multiple tumor types, including NSCLC.<sup><a href="#B14" class="usa-link" aria-describedby="B14">14</a>-<a href="#B18" class="usa-link" aria-describedby="B18">18</a></sup> Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, binds with high affinity to PD-1 receptors expressed on T cells and disrupts negative signaling induced by PD-ligand 1 (PD-L1) and PD-ligand 2 to restore T-cell effector function.<sup><a href="#B19" class="usa-link" aria-describedby="B19">19</a>,<a href="#B20" class="usa-link" aria-describedby="B20">20</a></sup> In heavily pretreated patients with advanced NSCLC, nivolumab monotherapy demonstrated an ORR of 17%, with 1-, 2-, and 3-year OS rates of 42%, 24%, and 18%, respectively, and a manageable safety profile.<sup><a href="#B14" class="usa-link" aria-describedby="B14">14</a></sup> These initial signals of efficacy and tolerability prompted two phase III trials that demonstrated a survival benefit for salvage nivolumab over docetaxel in patients with advanced pretreated NSCLC,<sup><a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a></sup> leading to its approval in the United States for treatment of patients with metastatic NSCLC whose disease has progressed on or after platinum-based chemotherapy and after an approved TKI therapy (if expressing <em>EGFR</em> or <em>ALK</em> genomic tumor aberrations).<sup><a href="#B23" class="usa-link" aria-describedby="B23">23</a></sup> Also, nivolumab is approved in the European Union for locally advanced or metastatic NSCLC after prior chemotherapy.<sup><a href="#B24" class="usa-link" aria-describedby="B24">24</a></sup></p> <p>Given the safety and efficacy of nivolumab in the second- or later-line settings, CheckMate 012 (<a href="https://clinicaltrials.gov/ct2/show/NCT01454102" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01454102</a>), a phase I, multicohort study, evaluated the potential benefit of nivolumab as monotherapy or combined with current standard therapies in first-line advanced NSCLC. Here, we report safety and efficacy from the full cohort of patients receiving first-line nivolumab monotherapy.</p></section><section id="s2"><h2 class="pmc_sec_title">METHODS</h2> <section id="s3"><h3 class="pmc_sec_title">Study Design and Treatment</h3> <p>This study was approved by local institutional review boards, and all patients or their legal representatives provided written informed consent before enrollment. Patients with stage IIIB to IV NSCLC who had no prior chemotherapy for advanced disease received nivolumab 3 mg/kg intravenous infusion on treatment day 1 and every 2 weeks thereafter until disease progression, discontinuation due to toxicity, withdrawal of consent, or loss to follow-up. Patients were permitted to continue study treatment beyond initial progressive disease, as defined by RECIST version 1.1,<sup><a href="#B25" class="usa-link" aria-describedby="B25">25</a></sup> if they were considered by the investigator to be deriving clinical benefit (continuing symptom or disease control despite radiographic progression) and tolerating study treatment. Patients who continued study therapy beyond progression were required to discontinue if subsequent imaging demonstrated an additional 10% increase in tumor burden from the time of initial progression.</p> <p>Follow-up visits after discontinuation of study therapy occurred 30 (± 14) and 100 (± 14) days after the last nivolumab dose. For patients who discontinued for reasons other than progressive disease, tumor assessments were performed every 3 months (± 14 days) until documented progression. Survival was evaluated every 12 weeks after the second follow-up visit. Patients were followed for treatment-related toxicities until they resolved, returned to baseline, or were deemed irreversible.</p></section><section id="s4"><h3 class="pmc_sec_title">Patients</h3> <p>Eligible patients had histologically or cytologically confirmed stage IIIB to IV NSCLC (any histology),<sup><a href="#B26" class="usa-link" aria-describedby="B26">26</a></sup> with radiographic proof of measurable disease according to RECIST V1.1.<sup><a href="#B25" class="usa-link" aria-describedby="B25">25</a></sup> Patients had to be age 18 years or older with an Eastern Cooperative Oncology Group performance status of 0 or 1; have adequate hematologic, hepatic, and renal function; and have a life expectancy of at least 3 months. Patients had not received prior chemotherapy for advanced NSCLC. However, prior adjuvant or neoadjuvant chemotherapy was allowed. Prior radiotherapy and EGFR TKI therapy was permitted if completed at least 2 weeks before study drug administration. Collection of pretreatment excisional, incisional, or core needle tumor biopsies (fine-needle aspiration was insufficient) was required for biomarker evaluation but was not used to select patients. Patients could begin nivolumab treatment before confirming that tumor samples were sufficient for biomarker evaluation. Patients with history of brain metastases were eligible if they had completed radiotherapy, surgery, or radiosurgery at least 2 weeks before enrollment and did not require steroids for control of cerebral edema. Exclusion criteria included a history of active, known, or suspected autoimmune disease and evidence of active infection with hepatitis B or C or HIV.</p></section><section id="s5"><h3 class="pmc_sec_title">Concomitant Treatments</h3> <p>Immunosuppressive agents, including immunosuppressive doses of systemic corticosteroids (eg, prednisone > 10 mg/d), and any use of concurrent hormonal therapy, immunotherapy, or standard or investigational agents for the treatment of NSCLC were prohibited during the study. However, a brief course of corticosteroids was permitted for prophylaxis (eg, contrast dye allergy) and corticosteroids or other immune-suppressive agents were allowed to manage symptomatic treatment-related immune toxicities.</p></section><section id="s6"><h3 class="pmc_sec_title">Study Assessments</h3> <section id="s7"><h4 class="pmc_sec_title">Safety Assessments.</h4> <p>The primary objective of the study was to assess the safety and tolerability of nivolumab monotherapy, as measured by the frequency of treatment-related adverse events (AEs) and through careful monitoring of laboratory abnormalities. Categories of select AEs (those with potential immunologic etiology that require more frequent monitoring or intervention) were based on a prespecified list of Medical Dictionary for Regulatory Activities terms. The causal relationship (related or not related) between study drug and AEs was determined by the investigator; severity of AEs was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.<sup><a href="#B27" class="usa-link" aria-describedby="B27">27</a></sup></p></section><section id="s8"><h4 class="pmc_sec_title">Efficacy Assessments.</h4> <p>The secondary study objective was antitumor activity of nivolumab monotherapy, as measured by ORR and PFS rate at 24 weeks using investigator-assessed tumor measurements, according to RECIST v1.1.<sup><a href="#B25" class="usa-link" aria-describedby="B25">25</a></sup> Tumor response was assessed by the investigator at the beginning of weeks 11, 17, 23, and every 3 months thereafter until disease progression. For patients continuing nivolumab treatment beyond initial progression, tumor assessments were repeated 6 weeks after initial progression and every 12 weeks thereafter. Clinical activity also was assessed by histology, smoking history, <em>EGFR</em> and Kirsten rat sarcoma viral oncogene homolog (<em>KRAS</em>) mutation status, and tumor PD-L1 expression (Data Supplement). OS was included as an exploratory efficacy end point.</p></section></section><section id="s9"><h3 class="pmc_sec_title">Statistical Analyses</h3> <p>Analyses of safety and efficacy, except for OS, are based on a March 2015 database lock; OS was updated based on an August 2015 database lock. Patient demographics, baseline characteristics, and frequency of AEs were summarized using descriptive statistics. All recorded AEs were coded according to Medical Dictionary for Regulatory Activities, version 17.0. ORR was defined as the proportion of all treated patients whose best overall response (BOR) was either a confirmed complete response or confirmed partial response, with corresponding two-sided 95% exact CIs calculated using the Clopper-Pearson method.<sup><a href="#B28" class="usa-link" aria-describedby="B28">28</a></sup> Estimated time-to-event end points (PFS rate at 24 weeks, median duration of response [DOR], PFS, and OS) were calculated using the Kaplan-Meier method, with two-sided 95% exact CIs derived via log-log transformation.<sup><a href="#B29" class="usa-link" aria-describedby="B29">29</a></sup></p></section></section><section id="s10"><h2 class="pmc_sec_title">RESULTS</h2> <section id="s11"><h3 class="pmc_sec_title">Patient Population and Disposition</h3> <p>Fifty-two patients with advanced NSCLC were treated with nivolumab monotherapy; 94% had stage IV disease, 75% (39 of 52) had tumors of nonsquamous histology, 15% (eight of 52) had <em>EGFR</em>-mutant tumors, and 79% (41 of 52) were former/current smokers (<a href="#T1" class="usa-link">Table 1</a>). Forty percent of patients had received prior radiotherapy, and 21% and 4% had received prior adjuvant and neoadjuvant systemic platinum-based therapy, respectively. Median follow-up for the overall population was 14.3 months (range, 0.2 to 30.1). At the time of analysis, 100% of patients (13 of 13) with squamous disease and 87% of patients with nonsquamous disease had discontinued nivolumab, most commonly because of disease progression (squamous, 77%; nonsquamous, 64%; Data Supplement).</p> <section class="tw xbox font-sm" id="T1"><h4 class="obj_head">Table 1.</h4> <div class="caption p"><p>Patient Characteristics and Summary of Prior Therapy</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <col width="62.71%" span="1"> <col width="37.29%" span="1"> <thead><tr> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Characteristic</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Total (N = 52)</th> </tr></thead> <tbody> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median age (range), years</td> <td valign="top" align="center" rowspan="1" colspan="1">67 (43-85)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td> <td valign="top" align="center" rowspan="1" colspan="1">26 (50)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td> <td valign="top" align="center" rowspan="1" colspan="1">26 (50)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Disease stage</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stage IIIB</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stage IV</td> <td valign="top" align="center" rowspan="1" colspan="1">49 (94)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Histology</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nonsquamous<a href="#t1n1" class="usa-link"><sup>*</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">39 (75)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Squamous</td> <td valign="top" align="center" rowspan="1" colspan="1">13 (25)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Tumor mutation status<a href="#t1n2" class="usa-link"><sup>†</sup></a> </td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> <em>EGFR</em> mutation status</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mutant<a href="#t1n3" class="usa-link"><sup>‡</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">8 (15)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exon 19 deletion</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> L858R</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wildtype</td> <td valign="top" align="center" rowspan="1" colspan="1">31 (60)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td> <td valign="top" align="center" rowspan="1" colspan="1">13 (25)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> <em>KRAS</em> mutation status</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mutant</td> <td valign="top" align="center" rowspan="1" colspan="1">9 (17)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Wildtype</td> <td valign="top" align="center" rowspan="1" colspan="1">10 (19)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown</td> <td valign="top" align="center" rowspan="1" colspan="1">33 (64)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">PD-L1 expression, %</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥ 1</td> <td valign="top" align="center" rowspan="1" colspan="1">32 (62)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥ 5</td> <td valign="top" align="center" rowspan="1" colspan="1">26 (50)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥ 10</td> <td valign="top" align="center" rowspan="1" colspan="1">20 (38)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥ 25</td> <td valign="top" align="center" rowspan="1" colspan="1">18 (35)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥ 50</td> <td valign="top" align="center" rowspan="1" colspan="1">12 (23)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unknown<a href="#t1n4" class="usa-link"><sup>§</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">6 (12)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Smoking status</td> <td valign="top" align="left" rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Never</td> <td valign="top" align="center" rowspan="1" colspan="1">11 (21)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Former</td> <td valign="top" align="center" rowspan="1" colspan="1">38 (73)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prior surgery</td> <td valign="top" align="center" rowspan="1" colspan="1">48 (92)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prior radiotherapy</td> <td valign="top" align="center" rowspan="1" colspan="1">21 (40)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prior systemic therapy</td> <td valign="top" align="center" rowspan="1" colspan="1">19 (37)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Regimen setting<a href="#t1n6" class="usa-link"><sup>||</sup></a> </td> <td valign="top" align="left" rowspan="1" colspan="1">?</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Adjuvant therapy</td> <td valign="top" align="center" rowspan="1" colspan="1">11 (21)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neoadjuvant therapy</td> <td valign="top" align="center" rowspan="1" colspan="1">2 (4)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Metastatic disease<a href="#t1n5" class="usa-link"><sup>¶</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">7 (13)</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"> <div class="fn" id="fn1_pmc"><p>NOTE. Data presented as No. (%) unless otherwise noted.</p></div> <div class="fn" id="fn2_pmc"><p>Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; TKI, tyrosine kinase inhibitor.</p></div> <div class="fn" id="t1n1"> <sup>*</sup><p class="display-inline">Includes three patients with histology type other.</p> </div> <div class="fn" id="t1n2"> <sup>†</sup><p class="display-inline">There were no patients with known <em>ALK</em> rearrangements.</p> </div> <div class="fn" id="t1n3"> <sup>‡</sup><p class="display-inline">Prior TKI therapy was allowed (but not required) for patients with <em>EGFR</em>-mutant tumors.</p> </div> <div class="fn" id="t1n4"> <sup>§</sup><p class="display-inline">Tumor programmed death–ligand 1 expression was not quantifiable in six patients, either because of suboptimal tissue amount or quality (eg, too few tumor cells or no cells, improper fixation, or sectioning artifacts; n = 5) or because tumor tissue was unavailable (n = 1).</p> </div> <div class="fn" id="t1n6"> <sup>||</sup><p class="display-inline">More than one setting per patient may be reflected in the frequency.</p> </div> <div class="fn" id="t1n5"> <sup><sup>¶</sup></sup><p class="display-inline">All patients who received prior systemic therapy for metastatic disease were treated with erlotinib.</p> </div> </div></section></section><section id="s12"><h3 class="pmc_sec_title">Safety</h3> <p>Treatment-related AEs of any grade were reported in 71% of patients (<a href="#T2" class="usa-link">Table 2</a>), most commonly (≥ 10% of patients) fatigue (29%), rash (19%), nausea (14%), diarrhea and pruritus (12% each), and arthralgia (10%). Most treatment-related AEs were of low severity. Grade 3 to 4 treatment-related AEs occurred in 10 patients (19%), including rash (two patients, 4%), increased amylase and lipase, increased ALT and AST, hyperglycemia, cardiac failure, dehydration and diarrhea, hyponatremia, lung infection, and pneumonitis (one patient each). Treatment-related AEs led to discontinuation in six patients (12%), including grade 4 increased ALT and grade 3 increased AST (one patient), and cardiac failure, hyperglycemia, increased lipase, diarrhea, and pneumonitis (all grade 3; one patient each). All but one patient (increased lipase) had resolution of these toxicities. Sixty-seven percent (four of six) of patients who discontinued because of treatment-related AEs had partial response as BOR; the remaining patients had stable disease (SD) as BOR.</p> <section class="tw xbox font-sm" id="T2"><h4 class="obj_head">Table 2.</h4> <div class="caption p"><p>Treatment-Related AEs Occurring in ≥ 5% of Patients With Advanced NSCLC Treated With Nivolumab Monotherapy</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <col width="46.6%" span="1"> <col width="25.38%" span="1"> <col width="28.02%" span="1"> <thead> <tr> <th rowspan="2" valign="top" align="center" scope="col" colspan="1">Event</th> <th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">All Patients (N = 52)</th> </tr> <tr> <th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">Any Grade<a href="#t2n1" class="usa-link"><sup>*</sup></a> </th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Grade 3-4<a href="#t2n2" class="usa-link"><sup>†</sup></a> </th> </tr> </thead> <tbody> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Any event</td> <td valign="top" align="center" rowspan="1" colspan="1">37 (71)</td> <td valign="top" align="center" rowspan="1" colspan="1">10 (19)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fatigue</td> <td valign="top" align="center" rowspan="1" colspan="1">15 (29)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Rash</td> <td valign="top" align="center" rowspan="1" colspan="1">10 (19)</td> <td valign="top" align="center" rowspan="1" colspan="1">2 (4)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nausea</td> <td valign="top" align="center" rowspan="1" colspan="1">7 (14)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Diarrhea</td> <td valign="top" align="center" rowspan="1" colspan="1">6 (12)</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pruritus</td> <td valign="top" align="center" rowspan="1" colspan="1">6 (12)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Arthralgia</td> <td valign="top" align="center" rowspan="1" colspan="1">5 (10)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Constipation</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hypothyroidism</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pneumonitis</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (2)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vomiting</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (6)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"> <div class="fn" id="fn9"><p>NOTE. Data presented as No. (%). Data are based on a March 2015 database lock. Includes events reported between first dose date and 100 days after the last dose of nivolumab. The causal relationship (related or not related) between study drug and AEs was determined by the investigator. Some patients had more than one AE.</p></div> <div class="fn" id="fn10"><p>Abbreviations: AE, adverse event; NSCLC, non–small-cell lung cancer.</p></div> <div class="fn" id="t2n1"> <sup>*</sup><p class="display-inline">No grade 5 events were reported.</p> </div> <div class="fn" id="t2n2"> <sup>†</sup><p class="display-inline">Other grade 3 to 4 treatment-related AEs were increased ALT (grade 4, n = 1), increased amylase, increased AST, cardiac failure, dehydration, hyperglycemia, hyponatremia, increased lipase, and lung infection (all grade 3, n = 1 each).</p> </div> </div></section><p>The most common (≥ 10% of patients) categories of treatment-related select AEs (Data Supplement) were skin (any grade, 25%; grade 3 to 4, 4%), endocrine (any grade, 14%; grade 3 to 4, 0%), and gastrointestinal (any grade, 12%; grade 3 to 4, 2%). All treatment-related select pulmonary events were pneumonitis (any grade, 6%; grade 3 to 4, 2%).</p> <p>At the time of analysis, 20 patients had died: 19 as a result of disease progression and one as a result of sepsis and lung infection (not related to study treatment). No treatment-related deaths were reported.</p></section><section id="s13"><h3 class="pmc_sec_title">Response and Tumor Kinetics</h3> <p>In the overall population, confirmed ORR was 23% (12 of 52), including four patients with ongoing complete responses (<a href="#T3" class="usa-link">Table 3</a>). An additional 27% of patients achieved SD for a disease control rate (DCR) of 50%; 19% (10 of 52) had SD lasting ≥ 21 weeks. Responses were durable (median DOR was not reached [NR]; range, 4.2 to 25.8+ months) and 75% (nine of 12) were achieved by the first tumor assessment (week 11). Reductions in tumor burden were observed regardless of NSCLC histology, and three patients had > 80% target lesion reduction by 18 weeks (<a href="#F1" class="usa-link">Figs 1A</a> and <a href="#F1" class="usa-link">1B</a>). Among patients with ongoing responses (67%; 8 of 12), response durations ranged from 5.3+ to 25.8+ months (<a href="#F1" class="usa-link">Fig 1C</a>). Three additional patients had nonconventional immune-related responses, with 46%, 43%, and 35% maximum reductions in target lesions and simultaneous appearance of new lesions; OS for these patients was 12.8+, 14.5+, and 10.2 months, respectively. Fifty-eight percent of patients (seven of 12) had responses that continued after discontinuing nivolumab for reasons other than progressive disease (<a href="#F1" class="usa-link">Fig 1C</a>).</p> <section class="tw xbox font-sm" id="T3"><h4 class="obj_head">Table 3.</h4> <div class="caption p"><p>Tumor Response in Patients With Advanced NSCLC Treated With Nivolumab Monotherapy<a href="#t3n1" class="usa-link"><sup>a</sup></a></p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <col width="34.03%" span="1"> <col width="21.99%" span="1"> <col width="21.99%" span="1"> <col width="21.99%" span="1"> <thead><tr> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Response/Survival</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Squamous (n = 13)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Nonsquamous (n = 39)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">All Patients (N = 52)</th> </tr></thead> <tbody> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Confirmed ORR,<a href="#t3n2" class="usa-link"><sup>b</sup></a> No. (%) [95% CI]</td> <td valign="top" align="center" rowspan="1" colspan="1">2 (15) [2 to 45]</td> <td valign="top" align="center" rowspan="1" colspan="1">10 (26) [13 to 42]</td> <td valign="top" align="center" rowspan="1" colspan="1">12 (23) [13 to 37]</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Confirmed DCR,<a href="#t3n3" class="usa-link"><sup>c</sup></a> No. (%) [95% CI]</td> <td valign="top" align="center" rowspan="1" colspan="1">8 (62) [32 to 86]</td> <td valign="top" align="center" rowspan="1" colspan="1">18 (46) [30 to 63]</td> <td valign="top" align="center" rowspan="1" colspan="1">26 (50) [36 to 64]</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ongoing responders,<a href="#t3n4" class="usa-link"><sup>d</sup></a> No. (%)</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (50)</td> <td valign="top" align="center" rowspan="1" colspan="1">7 (70)</td> <td valign="top" align="center" rowspan="1" colspan="1">8 (67)</td> </tr> <tr> <td valign="top" align="left" scope="col" rowspan="1" colspan="1">BOR,<a href="#t3n5" class="usa-link"><sup>e</sup></a> No. (%)</td> <td rowspan="1" colspan="1"></td> <td rowspan="1" colspan="1"></td> <td rowspan="1" colspan="1"></td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Confirmed CR</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (8)</td> <td valign="top" align="center" rowspan="1" colspan="1">3 (8)</td> <td valign="top" align="center" rowspan="1" colspan="1">4 (8)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Confirmed PR</td> <td valign="top" align="center" rowspan="1" colspan="1">1 (8)</td> <td valign="top" align="center" rowspan="1" colspan="1">7 (18)</td> <td valign="top" align="center" rowspan="1" colspan="1">8 (15)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SD</td> <td valign="top" align="center" rowspan="1" colspan="1">6 (46)</td> <td valign="top" align="center" rowspan="1" colspan="1">8 (21)</td> <td valign="top" align="center" rowspan="1" colspan="1">14 (27)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SD ≥ 21 weeks<a href="#t3n6" class="usa-link"><sup>f</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">3 (23)</td> <td valign="top" align="center" rowspan="1" colspan="1">7 (18)</td> <td valign="top" align="center" rowspan="1" colspan="1">10 (19)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Progressive disease</td> <td valign="top" align="center" rowspan="1" colspan="1">5 (38)</td> <td valign="top" align="center" rowspan="1" colspan="1">15 (38)</td> <td valign="top" align="center" rowspan="1" colspan="1">20 (38)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unable to determine</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> <td valign="top" align="center" rowspan="1" colspan="1">6 (15)<a href="#t3n7" class="usa-link"><sup>g</sup></a> </td> <td valign="top" align="center" rowspan="1" colspan="1">6 (12)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Estimated DOR,<a href="#t3n8" class="usa-link"><sup>h</sup></a> median (range), months</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (16.5 to 23.3+)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">PFS, median (range), months</td> <td valign="top" align="center" rowspan="1" colspan="1">3.5 (1.4 to 25.6+)</td> <td valign="top" align="center" rowspan="1" colspan="1">5.0 (< 0.1+ to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">3.6 (< 0.1+ to 28.0+)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">PFS at 24 weeks,<a href="#t3n9" class="usa-link"><sup>i</sup></a> % (95% CI)</td> <td valign="top" align="center" rowspan="1" colspan="1">31 (9 to 55)</td> <td valign="top" align="center" rowspan="1" colspan="1">45 (28 to 60)</td> <td valign="top" align="center" rowspan="1" colspan="1">41 (27 to 54)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">OS, median (range), months</td> <td valign="top" align="center" rowspan="1" colspan="1">16.8 (3.1 to 32.5+)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (0.2 to 35.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">19.4 (0.2 to 35.8+)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">1-year OS, % (95% CI)</td> <td valign="top" align="center" rowspan="1" colspan="1">76 (43 to 92)</td> <td valign="top" align="center" rowspan="1" colspan="1">72 (55 to 83)</td> <td valign="top" align="center" rowspan="1" colspan="1">73 (59 to 83)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">18-month OS, % (95% CI)</td> <td valign="top" align="center" rowspan="1" colspan="1">42 (16 to 67)</td> <td valign="top" align="center" rowspan="1" colspan="1">63 (45 to 76)</td> <td valign="top" align="center" rowspan="1" colspan="1">57 (42 to 70)</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"> <div class="fn" id="fn13"><p>NOTE. Not reached (NR) was due to a high percentage of ongoing response or insufficient number of events and/or follow up. Plus symbol (+) indicates a censored value.</p></div> <div class="fn" id="fn14"><p>Abbreviations: BOR, best overall response; CR, complete response; DCR, disease control rate; DOR, duration of response; NSCLC, non–small-cell lung cancer; ORR, objective response rate; OS, overall survival; PR, partial response; PFS, progression-free survival; SD, stable disease.</p></div> <div class="fn" id="t3n1"> <sup><sup>a</sup></sup><p class="display-inline">Data for response and PFS are based on a March 2015 database lock. Data for OS are based on an August 2015 database lock.</p> </div> <div class="fn" id="t3n2"> <sup><sup>b</sup></sup><p class="display-inline">Includes patients with initial observations of CR and PR that were subsequently confirmed by repeat scans performed no earlier than 4 weeks after the original observation.</p> </div> <div class="fn" id="t3n3"> <sup><sup>c</sup></sup><p class="display-inline">Includes patients with initial observations of CR and PR that were subsequently confirmed by repeat scans performed no earlier than 4 weeks after the original observation and patients with BOR of SD.</p> </div> <div class="fn" id="t3n4"> <sup><sup>d</sup></sup><p class="display-inline">Includes patients with confirmed CR or PR who neither progressed nor died within 100 days of last nivolumab dose.</p> </div> <div class="fn" id="t3n5"> <sup><sup>e</sup></sup><p class="display-inline">Tumor assessments up to initial disease progression or initiation of subsequent anticancer therapy, whichever occurred first, were considered for BOR assessment.</p> </div> <div class="fn" id="t3n6"> <sup><sup>f</sup></sup><p class="display-inline">The 21-week time point was chosen based on the timing of tumor assessments.</p> </div> <div class="fn" id="t3n7"> <sup><sup>g</sup></sup><p class="display-inline">Includes patients who discontinued trial therapy because of clinical progression of disease before first on-trial imaging assessment or patients only with on-treatment tumor assessments suggestive of, but that did not satisfy, the required minimum duration for SD.</p> </div> <div class="fn" id="t3n8"> <sup><sup>h</sup></sup><p class="display-inline">Time from first response to documented progression, death within 100 days of last nivolumab dose, or last tumor assessment before subsequent anticancer therapy (for censored data).</p> </div> <div class="fn" id="t3n9"> <sup><sup>i</sup></sup><p class="display-inline">PFS rate was defined as the probability of a patient remaining progression free and alive up to 24 weeks.</p> </div> </div></section><figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Fig 1.</h4> <p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5569692_JCO669929f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e181/5569692/61155edb4501/JCO669929f1.jpg" loading="lazy" height="581" width="458" alt="Fig 1."></a></p> <div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <figcaption><p>Characteristics of response in patients with advanced non–small-cell lung cancer treated with nivolumab monotherapy. Data are based on a March 2015 database lock. (A) Percent change in target lesion tumor burden from baseline over time. Only includes patients with baseline target lesion and one or more postbaseline target lesion assessments with nonmissing value (n = 49). Horizontal lines denote 30% decrease, 20% increase, and no change. (B) Best percent change in target lesion tumor burden from baseline. Only includes patients with baseline target lesion and one or more postbaseline target lesion assessments with nonmissing value (n = 49). Maximum percent reductions in target lesion tumor burden from baseline across all tumor assessments before subsequent therapy are used. Positive change in tumor burden indicates tumor growth; negative change in tumor burden indicates tumor reduction. Horizontal lines denote 30% decrease and 20% increase. Not all reductions of ≥ 30% from baseline are partial responses (ie, decrease in target lesion tumor burden but new or progressive nontarget lesions). (C) Time to and duration of response. CR, complete response; DOR, duration of response.</p></figcaption></figure></section><section id="s14"><h3 class="pmc_sec_title">Overall Survival and Progression-Free Survival</h3> <p>Median OS, an exploratory end point, was 19.4 months (range, 0.2 to 35.8+) for the overall population, and 16.8 months (range, 3.1 to 32.5+) and NR (range, 0.2 to 35.8+ months) for patients with squamous and nonsquamous histology, respectively (<a href="#T3" class="usa-link">Table 3</a> and <a href="#F2" class="usa-link">Fig 2A</a>). The 12-month OS rate was 73% (95% CI, 59% to 83%) for the overall population, and 76% (95% CI, 43% to 92%) and 72% (95% CI, 55% to 83%) for patients with squamous and nonsquamous histology, respectively. The 18-month OS rate was 57% (95% CI, 42% to 70%) for the overall population and 42% (95% CI, 16% to 67%) and 63% (95% CI, 45% to 76%) for patients with squamous and nonsquamous histology, respectively. Median PFS was 3.6 months (range, < 0.1+ to 28.0+ months), and the 24-week PFS rate was 41% (95% CI, 27% to 54%; <a href="#T3" class="usa-link">Table 3</a>). Median PFS and 24-week PFS rate were 3.5 months (range, 1.4 to 25.6+ months) and 31% (95% CI, 9% to 55%) in patients with squamous NSCLC, and 5.0 months (range, < 0.1+ to 28.0+ months) and 45% (95% CI, 28% to 60%) in patients with nonsquamous NSCLC (<a href="#T3" class="usa-link">Table 3</a> and <a href="#F2" class="usa-link">Fig 2B</a>).</p> <figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Fig 2.</h4> <p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=5569692_JCO669929f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e181/5569692/18d0ac2eb443/JCO669929f2.jpg" loading="lazy" height="419" width="464" alt="Fig 2."></a></p> <div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <figcaption><p>Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) by histology in patients with advanced non–small-cell lung cancer (NSCLC) treated with nivolumab monotherapy. (A) OS by NSCLC histology. Data for OS are based on an August 2015 database lock. (B) PFS by NSCLC histology. Data for PFS are based on a March 2015 database lock. Symbols denote censored observations.</p></figcaption></figure></section><section id="s15"><h3 class="pmc_sec_title">Efficacy by Tumor PD-L1 Expression</h3> <p>Tumor PD-L1 expression was not quantifiable in 12% of patients (six of 52), either because of suboptimal tissue amount or quality (eg, too few tumor cells or no cells, improper fixation, or sectioning artifacts; n = 5) or because tumor tissue was unavailable (n = 1). Of the 46 patients (88%) with tumor specimens evaluable for PD-L1 expression, 70% (32 of 46) and 30% (14 of 46) had ≥ 1% and < 1% PD-L1 expression, respectively; 57% (26 of 46) and 43% (20 of 46) had ≥ 5% and < 5% PD-L1 expression, respectively. Clinical activity was observed regardless of PD-L1 expression, with higher ORRs in patients whose tumors expressed PD-L1 versus patients with low tumor PD-L1 expression across all expression levels (<a href="#T4" class="usa-link">Table 4</a>). Confirmed ORR was 28% (nine of 32) and 14% (two of 14) in tumors with ≥ 1% and < 1% PD-L1 expression and 31% (eight of 26) and 15% (three of 20) in tumors with ≥ 5% and < 5% PD-L1 expression, respectively. Best percentage change in target lesion tumor burden from baseline by 1% PD-L1 expression is shown in the Data Supplement. There was no clear association between PFS or OS and baseline PD-L1 expression (Data Supplement).</p> <section class="tw xbox font-sm" id="T4"><h4 class="obj_head">Table 4.</h4> <div class="caption p"><p>Efficacy of Nivolumab Monotherapy by Baseline Tumor PD-L1 Expression<a href="#t4n1" class="usa-link"><sup>*</sup></a></p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <col width="9.85%" span="1"> <col width="9.68%" span="1"> <col width="15.84%" span="1"> <col width="11.44%" span="1"> <col width="12.32%" span="1"> <col width="17.6%" span="1"> <col width="11.44%" span="1"> <col width="11.83%" span="1"> <thead><tr> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">PD-L1 Expression, %</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Confirmed ORR<a href="#t4n2" class="usa-link"><sup>†</sup></a>, % (n/N)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median DOR<a href="#t4n3" class="usa-link"><sup>‡</sup></a>, Months (Range)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Ongoing Responders<a href="#t4n4" class="usa-link"><sup>§</sup></a>, %</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">PFS at 24 Weeks<a href="#t4n5" class="usa-link"><sup>||</sup></a>, % (95% CI)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">Median PFS, Months (Range)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">1-Year OS, % (95% CI)</th> <th valign="top" align="center" scope="col" rowspan="1" colspan="1">18-Month OS, % (95% CI)</th> </tr></thead> <tbody> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">≥ 50</td> <td valign="top" align="center" rowspan="1" colspan="1">50 (6/12)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (5.3+ to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">83</td> <td valign="top" align="center" rowspan="1" colspan="1">58 (27 to 80)</td> <td valign="top" align="center" rowspan="1" colspan="1">8.3 (2.2 to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">83 (48 to 96)</td> <td valign="top" align="center" rowspan="1" colspan="1">83 (48 to 96)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">≥ 25</td> <td valign="top" align="center" rowspan="1" colspan="1">44 (8/18)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">75</td> <td valign="top" align="center" rowspan="1" colspan="1">50 (26 to 70)</td> <td valign="top" align="center" rowspan="1" colspan="1">5.8 (0.2 to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">78 (51 to 91)</td> <td valign="top" align="center" rowspan="1" colspan="1">71 (43 to 87)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">≥ 10</td> <td valign="top" align="center" rowspan="1" colspan="1">40 (8/20)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">75</td> <td valign="top" align="center" rowspan="1" colspan="1">45 (23 to 65)</td> <td valign="top" align="center" rowspan="1" colspan="1">5.2 (0.2 to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">80 (55 to 92)</td> <td valign="top" align="center" rowspan="1" colspan="1">68 (41 to 84)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">≥ 5</td> <td valign="top" align="center" rowspan="1" colspan="1">31 (8/26)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">75</td> <td valign="top" align="center" rowspan="1" colspan="1">40 (21 to 58)</td> <td valign="top" align="center" rowspan="1" colspan="1">3.5 (< 0.1+ to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">73 (52 to 86)</td> <td valign="top" align="center" rowspan="1" colspan="1">54 (32 to 71)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">≥ 1</td> <td valign="top" align="center" rowspan="1" colspan="1">28 (9/32)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 25.8+)</td> <td valign="top" align="center" rowspan="1" colspan="1">78</td> <td valign="top" align="center" rowspan="1" colspan="1">39 (22 to 55)</td> <td valign="top" align="center" rowspan="1" colspan="1">3.5 (< 0.1+ to 28.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">69 (50 to 82)</td> <td valign="top" align="center" rowspan="1" colspan="1">53 (34 to 70)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">< 50</td> <td valign="top" align="center" rowspan="1" colspan="1">15 (5/34)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (4.2 to 12.6+)</td> <td valign="top" align="center" rowspan="1" colspan="1">60</td> <td valign="top" align="center" rowspan="1" colspan="1">36 (20 to 52)</td> <td valign="top" align="center" rowspan="1" colspan="1">2.4 (< 0.1+ to 16.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">68 (49 to 81)</td> <td valign="top" align="center" rowspan="1" colspan="1">48 (30 to 64)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">< 25</td> <td valign="top" align="center" rowspan="1" colspan="1">11 (3/28)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (5.8 to 9.5+)</td> <td valign="top" align="center" rowspan="1" colspan="1">67</td> <td valign="top" align="center" rowspan="1" colspan="1">36 (18 to 54)</td> <td valign="top" align="center" rowspan="1" colspan="1">2.4 (< 0.1+ to 16.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">68 (47 to 82)</td> <td valign="top" align="center" rowspan="1" colspan="1">48 (29 to 66)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">< 10</td> <td valign="top" align="center" rowspan="1" colspan="1">12 (3/26)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (5.8 to 9.5+)</td> <td valign="top" align="center" rowspan="1" colspan="1">67</td> <td valign="top" align="center" rowspan="1" colspan="1">39 (20 to 58)</td> <td valign="top" align="center" rowspan="1" colspan="1">3.5 (< 0.1+ to 16.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">65 (44 to 80)</td> <td valign="top" align="center" rowspan="1" colspan="1">49 (28 to 66)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">< 5</td> <td valign="top" align="center" rowspan="1" colspan="1">15 (3/20)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (5.8 to 9.5+)</td> <td valign="top" align="center" rowspan="1" colspan="1">67</td> <td valign="top" align="center" rowspan="1" colspan="1">45 (22 to 65)</td> <td valign="top" align="center" rowspan="1" colspan="1">5.0 (< 0.1+ to 16.0+)</td> <td valign="top" align="center" rowspan="1" colspan="1">70 (45 to 85)</td> <td valign="top" align="center" rowspan="1" colspan="1">60 (36 to 78)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">< 1</td> <td valign="top" align="center" rowspan="1" colspan="1">14 (2/14)</td> <td valign="top" align="center" rowspan="1" colspan="1">NR (5.8 to 9.5+)</td> <td valign="top" align="center" rowspan="1" colspan="1">50</td> <td valign="top" align="center" rowspan="1" colspan="1">50 (21 to 74)</td> <td valign="top" align="center" rowspan="1" colspan="1">6.6 (< 0.1+ to 12.4)</td> <td valign="top" align="center" rowspan="1" colspan="1">79 (47 to 93)</td> <td valign="top" align="center" rowspan="1" colspan="1">64 (34 to 83)</td> </tr> <tr> <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unknown</td> <td valign="top" align="center" rowspan="1" colspan="1">17 (1/6)</td> <td valign="top" align="center" rowspan="1" colspan="1">16.5 (16.5 to 16.5)</td> <td valign="top" align="center" rowspan="1" colspan="1">0</td> <td valign="top" align="center" rowspan="1" colspan="1">NC</td> <td valign="top" align="center" rowspan="1" colspan="1">3.7 (1.2+ to 24.7)</td> <td valign="top" align="center" rowspan="1" colspan="1">83 (27 to 97)</td> <td valign="top" align="center" rowspan="1" colspan="1">NC</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/T4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"> <div class="fn" id="fn24"><p>NOTE. NR due to high percentage of ongoing response. Plus symbol (+) indicates a censored value.</p></div> <div class="fn" id="fn25"><p>Abbreviations: CR, complete response; DOR, duration of response; NC, not calculated; NR, not reached; ORR, objective response rate; OS, overall survival; PD-L1, programmed death–ligand 1; PFS, progression-free survival; PR, partial response.</p></div> <div class="fn" id="t4n1"> <sup>*</sup><p class="display-inline">Data for response and PFS are based on a March 2015 database lock. Data for OS are based on an August 2015 database lock.</p> </div> <div class="fn" id="t4n2"> <sup>†</sup><p class="display-inline">Includes patients with initial observations of CR and PR that were subsequently confirmed by repeat scans performed no earlier than 4 weeks after the original observation.</p> </div> <div class="fn" id="t4n3"> <sup>‡</sup><p class="display-inline">Time from first response to documented progression, death within 100 days of last nivolumab dose, or last tumor assessment before subsequent anticancer therapy (for censored data).</p> </div> <div class="fn" id="t4n4"> <sup>§</sup><p class="display-inline">Includes patients with confirmed CR or PR who neither progressed nor died within 100 days of last nivolumab dose.</p> </div> <div class="fn" id="t4n5"> <sup>||</sup><p class="display-inline">PFS rate was defined as the probability of a patient remaining progression-free and alive up to 24 weeks.</p> </div> </div></section></section><section id="s16"><h3 class="pmc_sec_title">Efficacy by Smoking History and by <em>EGFR</em> and <em>KRAS</em> Mutation Status</h3> <p>Confirmed ORRs and disease control rates were numerically higher among patients who had a history of smoking (current, 33% [one of three] and 67% [two of three]; former, 26% [10 of 38] and 53% [20 of 38]; and never, 9% [one of 11] and 36% [four of 11]; Data Supplement). Median PFS also seemed longer in current (10.5 months, [range, 2.2 to 14.5]) and former (3.7 months [range, < 0.1+ to 28.0+]) smokers compared with never smokers (2.0 months [range, < 0.1+ to 8.1]).</p> <p>Among patients with nonsquamous NSCLC, responses occurred regardless of <em>EGFR</em> or <em>KRAS</em> mutation status (Data Supplement). ORR in patients with <em>EGFR</em>-mutant, <em>EGFR</em>-wildtype, <em>KRAS</em>-mutant, and <em>KRAS</em>-wildtype tumors was 14% (one of seven), 30% (nine of 30), 33% (three of nine), and 25% (two of eight), respectively. Median PFS was numerically shorter and the 24-week PFS rate numerically lower for patients with <em>EGFR</em>-mutant tumors (1.8 months [range, 0.2 to 7.6+ months] and 14% [95% CI, 1% to 46%]) versus patients with <em>EGFR</em>-wildtype tumors (6.6 months [range, < 0.1+ to 28.0+ months] and 51% [95% CI, 30% to 68%]). Conversely, median PFS was numerically longer and the 24-week PFS rate numerically higher for patients with <em>KRAS</em>-mutant tumors (11.8 months [range, < 0.1+ to 28.0+ months] and 88% [95% CI, 39% to 98%]) versus patients with <em>KRAS</em>-wildtype tumors (2.3 months [range, 1.2+ to 11.6+ months] and 29% [95% CI, 4% to 61%]).</p></section></section><section id="s17"><h2 class="pmc_sec_title">DISCUSSION</h2> <p>Current treatment algorithms for first-line advanced non–<em>EGFR</em>/<em>ALK-</em>driven NSCLC include PT-DC with or without bevacizumab, with modest response rates and survival, and risk for significant toxicity.<sup><a href="#B1" class="usa-link" aria-describedby="B1">1</a>-<a href="#B7" class="usa-link" aria-describedby="B7">7</a></sup> Alternative strategies are clearly needed to improve survival with better tolerance. Here, we show robust activity of nivolumab in the first-line setting, with good tolerance relative to standard first-line chemotherapy. Although results are limited by a highly selected population without randomization to standard chemotherapy, DOR (NR, range 4.2 to 25.8+ months) and survival (median OS, 19.4 months; 1 year and 18-month OS, 73% and 57%, respectively) are encouraging, far exceeding expectations with chemotherapy alone (median DOR, 4.5 to 9.4 months; median OS, 8.1 to 10.3 months; 1-year OS rates, 30% to 44%).<sup><a href="#B1" class="usa-link" aria-describedby="B1">1</a>-<a href="#B6" class="usa-link" aria-describedby="B6">6</a></sup> Furthermore, durable, complete clinical responses in four patients would be unexpected with chemotherapy and speaks to the potential of immunotherapy.</p> <p>As first-line therapy, nivolumab was well tolerated, with 19% of patients reporting grade 3 to 4 treatment-related AEs and no treatment-related deaths. In contrast to typical toxicities of PT-DC,<sup><a href="#B1" class="usa-link" aria-describedby="B1">1</a>,<a href="#B4" class="usa-link" aria-describedby="B4">4</a>-<a href="#B6" class="usa-link" aria-describedby="B6">6</a></sup> no cases of neutropenia, thrombocytopenia, or anemia were observed with nivolumab monotherapy. Consistent with prior nivolumab studies,<sup><a href="#B14" class="usa-link" aria-describedby="B14">14</a>,<a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a>,<a href="#B30" class="usa-link" aria-describedby="B30">30</a></sup> treatment-related select AEs affecting the skin, endocrine, gastrointestinal, and pulmonary organ classes were generally of low grade (grade 3 to 4, 0% to 4% across categories) and manageable with drug interruption or discontinuation, immune-suppressive agents (primarily corticosteroids), and/or hormone replacement per established guidelines. Six percent of patients (three of 52) developed pneumonitis, with one high-grade event (grade 3) treated successfully with corticosteroids.</p> <p>As with any systemic anticancer therapy, patient selection on the basis of clinical and/or molecular features promises to spare patients from potentially toxic therapies with low likelihood of benefit, allowing timely treatment with other therapies. Currently, first-line therapy for patients with advanced non–<em>EGFR/ALK</em>-driven lung cancer is based on histology, without established predictive molecular markers.<sup><a href="#B2" class="usa-link" aria-describedby="B2">2</a></sup> The value of tumor PD-L1 expression as a predictive biomarker for benefit with PD-1–axis inhibitors like nivolumab has not been fully established. Although pembrolizumab, another anti–PD-1 antibody, is currently approved for use only in PD-L1–positive, previously treated advanced NSCLC (on the basis of phase I data),<sup><a href="#B31" class="usa-link" aria-describedby="B31">31</a></sup> nivolumab use in this setting does not require tumor PD-L1 expression. Phase III trials leading to the approval of nivolumab as salvage therapy in advanced NSCLC did consider the predictive value of PD-L1 expression as a secondary end point,<sup><a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a></sup> suggesting a higher magnitude of benefit with nivolumab in patients with PD-L1–expressing nonsquamous NSCLC.<sup><a href="#B22" class="usa-link" aria-describedby="B22">22</a></sup> However, the absence of PD-L1 expression did not preclude response to or compromise survival with nivolumab in patients with squamous or nonsquamous NSCLC.<sup><a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a></sup> In the first-line setting, where chemotherapy has a higher response rate and greater survival advantage than in the second-line setting,<sup><a href="#B2" class="usa-link" aria-describedby="B2">2</a></sup> tumor PD-L1 expression may have a more important role in selecting a PD-1–axis inhibitor over standard chemotherapy. In the current study, responses were noted regardless of tumor PD-L1 expression; however, numerically higher ORRs were observed in patients whose tumors expressed PD-L1, with a trend toward greater response as PD-L1 expression level increased. Despite the limitations of quantifying PD-L1 expression—a continuous variable—using arbitrary cutoffs, results from this exploratory analysis, and the higher prevalence of PD-L1 expression observed in the first-line versus second- or later-line settings,<sup><a href="#B21" class="usa-link" aria-describedby="B21">21</a>,<a href="#B22" class="usa-link" aria-describedby="B22">22</a></sup> may support the use of nivolumab as first-line therapy for advanced PD-L1–expressing NSCLC. Two phase III trials are evaluating the predictive role of PD-L1 for nivolumab efficacy in the first-line setting. CheckMate 026 (<a href="https://clinicaltrials.gov/ct2/show/NCT02041533" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02041533</a>) is evaluating nivolumab versus standard PT-DC in patients with stage IV or recurrent PD-L1–positive NSCLC who had no prior chemotherapy for advanced disease and has completed accrual. The other trial, CheckMate 227 (<a href="https://clinicaltrials.gov/ct2/show/NCT02477826" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT02477826</a>), is evaluating nivolumab or nivolumab combined with ipilimumab versus standard PT-DC with or without nivolumab.</p> <p>As observed in other trials evaluating nivolumab as salvage therapy for advanced NSCLC, smoking history seemed to influence nivolumab activity, although the small number of patients limits conclusions. One potential explanation for lower activity in never-smokers has been lower tumor mutational load and associated neoantigens expected in these populations, with less-immunogenic tumors. Indeed, preliminary data suggest increased sensitivity to immune-checkpoint inhibitors in patients with tumors bearing a high mutational load (eg, smoking-associated lung cancer).<sup><a href="#B32" class="usa-link" aria-describedby="B32">32</a>,<a href="#B33" class="usa-link" aria-describedby="B33">33</a></sup></p> <p>In conclusion, nivolumab monotherapy as first-line therapy for patients with advanced NSCLC was generally well tolerated, showing promising activity with a manageable safety profile. Nivolumab is currently being evaluated in phase III trials versus standard first-line therapies for patients with PD-L1–positive advanced NSCLC.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgment</h2> <p>We thank the patients and their families, as well as the investigators and study teams, for making this trial possible; the staff at Dako North America for collaborative development of the automated PD-L1 immunohistochemistry assay; and Suresh Alaparthy for serving as protocol manager. Medical writing and editorial assistance were provided by Elyse Smith and Anne Cooper, of StemScientific, with funding from Bristol-Myers Squibb.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2> <div class="fn-group p font-secondary-light font-sm"> <div class="fn p" id="fn1"><p>Supported by Bristol-Myers Squibb.</p></div> <div class="fn p" id="fn3"><p>Authors’ disclosures of potential conflicts of interest are found in the article online at <a href="http://www.jco.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.jco.org</a>. Author contributions are found at the end of this article.</p></div> <div class="fn p" id="fn33"><p>Clinical trial information: <a href="https://clinicaltrials.gov/ct2/show/NCT01454102" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT01454102</a>.</p></div> <div class="fn p" id="fn2"><p>Presented in part at the European Cancer Congress Annual Meeting, Vienna, Austria, September 25-29, 2015; and the American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 29-June 2, 2015.</p></div> <div class="fn p" id="fn35"><p>See accompanying editorial on page <a href="https://pubmed.ncbi.nlm.nih.gov/27382094/" class="usa-link">2953</a></p></div> </div></section><section id="s19"><h2 class="pmc_sec_title">AUTHOR CONTRIBUTIONS</h2> <p><strong>Conception and design:</strong> Scott Gettinger, Julie Brahmer, Frances A. Shepherd, Scott Antonia, Yun Shen, Christopher T. Harbison, Matthew D. Hellmann</p> <p><strong>Provision of study materials or patients:</strong> Laura Q. Chow, Hossein Borghaei, Julie Brahmer, Frances A. Shepherd, Rosalyn A. Juergens, Scott A. Laurie, Matthew D. Hellmann</p> <p><strong>Collection and assembly of data:</strong> Scott Gettinger, Naiyer A. Rizvi, Laura Q. Chow, Hossein Borghaei, Julie Brahmer, Neal Ready, David E. Gerber, Scott Antonia, Jonathan W. Goldman, Faith E. Nathan, Matthew D. Hellmann</p> <p><strong>Data analysis and interpretation:</strong> Scott Gettinger, Laura Q. Chow, Hossein Borghaei, Julie Brahmer, Neal Ready, David E. Gerber, Scott Antonia, Jonathan W. Goldman, Rosalyn A. Juergens, Scott A. Laurie, Faith E. Nathan, Yun Shen, Christopher T. Harbison, Matthew D. Hellmann</p> <p><strong>Manuscript writing:</strong> All authors</p> <p><strong>Final approval of manuscript:</strong> All authors</p></section><section id="s20"><h2 class="pmc_sec_title">AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</h2> <section id="s21"><h3 class="pmc_sec_title">Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer</h3> <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <a href="http://www.asco.org/rwc" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.asco.org/rwc</a> or <a href="http://jco.ascopubs.org/site/ifc" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">jco.ascopubs.org/site/ifc</a>.</p></section><section id="s22"><h3 class="pmc_sec_title">Scott Gettinger</h3> <p><strong>Consulting or Advisory Role:</strong> Janssen Pharmaceuticals, Bristol-Myers Squibb, ARIAD Pharmaceuticals</p> <p><strong>Research Funding:</strong> Bristol-Myers Squibb (Inst), Genentech (Inst), ARIAD Pharmaceuticals (Inst), AstraZeneca/MedImmune (Inst), Boehringer Ingelheim (Inst), Incyte (Inst), Pfizer (Inst)</p></section><section id="s23"><h3 class="pmc_sec_title">Naiyer A. Rizvi</h3> <p><strong>Stock or Other Ownership:</strong> Gritstone Oncology</p> <p><strong>Honoraria:</strong> Merck Sharp & Dohme</p> <p><strong>Consulting or Advisory Role:</strong> AstraZeneca/MedImmune, Genentech, Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb</p></section><section id="s24"><h3 class="pmc_sec_title">Laura Q. Chow</h3> <p><strong>Honoraria:</strong> Amgen, Astellas Pharma</p> <p><strong>Consulting or Advisory Role:</strong> Merck, Novartis, Emergent BioSolutions, Amgen, Bristol-Myers Squibb, Seattle Genetics</p> <p><strong>Research Funding:</strong> Genentech (Inst), Pfizer (Inst), Merck (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), VentiRx Pharmaceuticals (Inst), AstraZeneca/MedImmune (Inst), Eli Lilly (Inst), OSI Pharmaceuticals (Inst), GlaxoSmithKline/NCCN (Inst), Incyte (Inst)</p> <p><strong>Travel, Accommodations, Expenses:</strong> Merck, Novartis</p></section><section id="s25"><h3 class="pmc_sec_title">Hossein Borghaei</h3> <p><strong>Honoraria:</strong> Bristol-Myers Squibb, Celgene</p> <p><strong>Consulting or Advisory Role:</strong> Bristol-Myers Squibb, Eli Lilly, Celgene, Clovis Oncology, Genentech</p> <p><strong>Research Funding:</strong> Millennium Pharmaceuticals (Inst)</p> <p><strong>Travel, Accommodations, Expenses:</strong> Bristol-Myers Squibb, Eli Lilly, Clovis Oncology, Celgene, Genentech</p></section><section id="s26"><h3 class="pmc_sec_title">Julie Brahmer</h3> <p><strong>Consulting or Advisory Role:</strong> Merck KGaA, Bristol-Myers Squibb, Eli Lilly</p> <p><strong>Research Funding:</strong> Bristol-Myers Squibb (Inst), Merck (Inst), AstraZeneca (Inst), Celgene (Inst)</p> <p><strong>Travel, Accommodations, Expenses:</strong> Bristol-Myers Squibb, Merck</p> <p><strong>Other Relationship:</strong> Bristol-Myers Squibb</p></section><section id="s27"><h3 class="pmc_sec_title">Neal Ready</h3> <p><strong>Honoraria:</strong> Bristol-Myers Squibb, Celgene, Heat Biologics</p> <p><strong>Travel, Accommodations, Expenses:</strong> AstraZeneca</p></section><section id="s28"><h3 class="pmc_sec_title">David E. Gerber</h3> <p><strong>Stock or Other Ownership:</strong> Gilead Sciences</p> <p><strong>Research Funding:</strong> ImmunoGen (Inst), ArQule (Inst), Synta Pharmaceuticals (Inst), Genentech (Inst), Celgene (Inst), ImClone Systems (Inst), BerGenBio (Inst)</p> <p><strong>Patents, Royalties, Other Intellectual Property:</strong> Royalties from Oxford University Press from two books; royalties from Decision Support in Medicine from the Clinical Decision Support–Oncology on-line program</p> <p><strong>Travel, Accommodations, Expenses:</strong> Eli Lilly, ArQule, Eli Lilly</p></section><section id="s29"><h3 class="pmc_sec_title">Frances A. Shepherd</h3> <p><strong>Stock or Other Ownership:</strong> Eli Lilly, AstraZeneca</p> <p><strong>Honoraria:</strong> Eli Lilly, AstraZeneca, Bristol-Myers Squibb, Merck Serono, Genentech, Merck/Schering Plough, Boehringer Ingelheim</p> <p><strong>Consulting or Advisory Role:</strong> Eli Lilly, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Recombio, Synta Pharmaceuticals, Bristol-Myers Squibb</p> <p><strong>Research Funding:</strong> Boehringer Ingelheim (Inst)</p></section><section id="s30"><h3 class="pmc_sec_title">Scott Antonia</h3> <p><strong>Stock or Other Ownership:</strong> Cellular Biomedicine Group</p> <p><strong>Honoraria:</strong> AstraZeneca, Bristol-Myers Squibb, Merck, Boehringer Ingelheim</p> <p><strong>Consulting or Advisory Role:</strong> Bristol-Myers Squibb, AstraZeneca, Merck, Boehringer Ingelheim</p> <p><strong>Travel, Accommodations, Expenses:</strong> Bristol-Myers Squibb, AstraZeneca, Merck, Boehringer Ingelheim </p></section><section id="s31"><h3 class="pmc_sec_title">Jonathan W. Goldman</h3> <p><strong>Honoraria:</strong> Clovis Oncology, Genentech, Bristol-Myers Squibb</p> <p><strong>Research Funding:</strong> Lilly, Genentech/Roche, Astex Pharmaceuticals, Synta Pharmaceuticals, Clovis Oncology, Bristol-Myers Squibb, AstraZeneca/MedImmune, Threshold Pharmaceuticals</p></section><section id="s32"><h3 class="pmc_sec_title">Rosalyn A. Juergens</h3> <p><strong>Honoraria:</strong> Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim, Beta Pharma, AstraZeneca, AstraZeneca/MedImmune, Roche Canada, Merck Sharp & Dohme</p> <p><strong>Consulting or Advisory Role:</strong> AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche Canada</p> <p><strong>Research Funding:</strong> AstraZeneca/MedImmune (Inst), Bristol-Myers Squibb (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst)</p></section><section id="s33"><h3 class="pmc_sec_title">Scott A. Laurie</h3> <p><strong>Honoraria:</strong> Pfizer, Bayer AG, Novartis, Boehringer Ingelheim </p></section><section id="s34"><h3 class="pmc_sec_title">Faith E. Nathan</h3> <p><strong>Employment:</strong> Bristol-Myers Squibb</p> <p><strong>Stock or Other Ownership:</strong> Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Eli Lilly</p></section><section id="s35"><h3 class="pmc_sec_title">Yun Shen</h3> <p><strong>Employment:</strong> Bristol-Myers Squibb, Bristol-Myers Squibb (I)</p> <p><strong>Stock or Other Ownership:</strong> Bristol-Myers Squibb, Bristol-Myers Squibb (I)</p></section><section id="s36"><h3 class="pmc_sec_title">Christopher T. Harbison</h3> <p><strong>Employment:</strong> Bristol-Myers Squibb</p> <p><strong>Stock or Other Ownership:</strong> Bristol-Myers Squibb</p></section><section id="s37"><h3 class="pmc_sec_title">Matthew D. Hellmann</h3> <p><strong>Consulting or Advisory Role:</strong> Third Rock Ventures, Bristol-Myers Squibb, Merck, Genentech, Alexion Pharmaceuticals, Inovio Biomedical, AstraZeneca/MedImmune</p> <p><strong>Research Funding:</strong> Bristol-Myers Squibb</p></section></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2> <section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none"> <li id="B1"> <span class="label">1.</span><cite>Kelly K Crowley J Bunn PA Jr, etal: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: A Southwest Oncology Group trial J Clin Oncol 19:3210–3218,2001</cite> [<a href="https://doi.org/10.1200/JCO.2001.19.13.3210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11432888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Randomized%20phase%20III%20trial%20of%20paclitaxel%20plus%20carboplatin%20versus%20vinorelbine%20plus%20cisplatin%20in%20the%20treatment%20of%20patients%20with%20advanced%20non--small-cell%20lung%20cancer:%20A%20Southwest%20Oncology%20Group%20trial&author=K%20Kelly&author=J%20Crowley&author=PA%20Bunn&volume=19&publication_year=2001&pages=3210-3218&pmid=11432888&doi=10.1200/JCO.2001.19.13.3210&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B2"> <span class="label">2.</span><cite> National Comprehensive Cancer Network: NSCLC Guidelines v7. <a href="http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl</a>.</cite> </li> <li id="B3"> <span class="label">3.</span><cite>Sandler A Gray R Perry MC, etal: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355:2542–2550,2006</cite> [<a href="https://doi.org/10.1056/NEJMoa061884" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17167137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Paclitaxel-carboplatin%20alone%20or%20with%20bevacizumab%20for%20non-small-cell%20lung%20cancer&author=A%20Sandler&author=R%20Gray&author=MC%20Perry&volume=355&publication_year=2006&pages=2542-2550&pmid=17167137&doi=10.1056/NEJMoa061884&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B4"> <span class="label">4.</span><cite>Scagliotti GV De Marinis F Rinaldi M, etal: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20:4285–4291,2002</cite> [<a href="https://doi.org/10.1200/JCO.2002.02.068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12409326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Phase%20III%20randomized%20trial%20comparing%20three%20platinum-based%20doublets%20in%20advanced%20non-small-cell%20lung%20cancer&author=GV%20Scagliotti&author=F%20De%20Marinis&author=M%20Rinaldi&volume=20&publication_year=2002&pages=4285-4291&pmid=12409326&doi=10.1200/JCO.2002.02.068&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B5"> <span class="label">5.</span><cite>Scagliotti GV Parikh P von Pawel J, etal: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26:3543–3551,2008</cite> [<a href="https://doi.org/10.1200/JCO.2007.15.0375" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18506025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Phase%20III%20study%20comparing%20cisplatin%20plus%20gemcitabine%20with%20cisplatin%20plus%20pemetrexed%20in%20chemotherapy-naive%20patients%20with%20advanced-stage%20non-small-cell%20lung%20cancer&author=GV%20Scagliotti&author=P%20Parikh&author=J%20von%20Pawel&volume=26&publication_year=2008&pages=3543-3551&pmid=18506025&doi=10.1200/JCO.2007.15.0375&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B6"> <span class="label">6.</span><cite>Schiller JH Harrington D Belani CP, etal: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346:92–98,2002</cite> [<a href="https://doi.org/10.1056/NEJMoa011954" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11784875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Comparison%20of%20four%20chemotherapy%20regimens%20for%20advanced%20non-small-cell%20lung%20cancer&author=JH%20Schiller&author=D%20Harrington&author=CP%20Belani&volume=346&publication_year=2002&pages=92-98&pmid=11784875&doi=10.1056/NEJMoa011954&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B7"> <span class="label">7.</span><cite>Patel JD Socinski MA Garon EB, etal: PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer J Clin Oncol 31:4349–4357,2013</cite> [<a href="https://doi.org/10.1200/JCO.2012.47.9626" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4881367/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24145346/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=PointBreak:%20A%20randomized%20phase%20III%20study%20of%20pemetrexed%20plus%20carboplatin%20and%20bevacizumab%20followed%20by%20maintenance%20pemetrexed%20and%20bevacizumab%20versus%20paclitaxel%20plus%20carboplatin%20and%20bevacizumab%20followed%20by%20maintenance%20bevacizumab%20in%20patients%20with%20stage%20IIIB%20or%20IV%20nonsquamous%20non-small-cell%20lung%20cancer&author=JD%20Patel&author=MA%20Socinski&author=EB%20Garon&volume=31&publication_year=2013&pages=4349-4357&pmid=24145346&doi=10.1200/JCO.2012.47.9626&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B8"> <span class="label">8.</span><cite>Haaland B Tan PS de Castro G Jr, etal: Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations J Thorac Oncol 9:805–811,2014</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000156" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4219539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24787964/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Thorac%20Oncol&title=Meta-analysis%20of%20first-line%20therapies%20in%20advanced%20non-small-cell%20lung%20cancer%20harboring%20EGFR-activating%20mutations&author=B%20Haaland&author=PS%20Tan&author=G%20de%20Castro&volume=9&publication_year=2014&pages=805-811&pmid=24787964&doi=10.1097/JTO.0000000000000156&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B9"> <span class="label">9.</span><cite>Kuykendall A, Chiappori A: Advanced EGFR mutation-positive non-small-cell lung cancer: Case report, literature review, and treatment recommendations Cancer Contr 21:67–73,2014</cite> [<a href="https://doi.org/10.1177/107327481402100110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24357744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Contr&title=Advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer:%20Case%20report,%20literature%20review,%20and%20treatment%20recommendations&author=A%20Kuykendall&author=A%20Chiappori&volume=21&publication_year=2014&pages=67-73&pmid=24357744&doi=10.1177/107327481402100110&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B10"> <span class="label">10.</span><cite>Rosell R Carcereny E Gervais R, etal: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial Lancet Oncol 13:239–246,2012</cite> [<a href="https://doi.org/10.1016/S1470-2045(11)70393-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22285168/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&title=Erlotinib%20versus%20standard%20chemotherapy%20as%20first-line%20treatment%20for%20European%20patients%20with%20advanced%20EGFR%20mutation-positive%20non-small-cell%20lung%20cancer%20(EURTAC):%20A%20multicentre,%20open-label,%20randomised%20phase%203%20trial&author=R%20Rosell&author=E%20Carcereny&author=R%20Gervais&volume=13&publication_year=2012&pages=239-246&pmid=22285168&doi=10.1016/S1470-2045(11)70393-X&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B11"> <span class="label">11.</span><cite>Sequist LV Yang JC Yamamoto N, etal: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31:3327–3334,2013</cite> [<a href="https://doi.org/10.1200/JCO.2012.44.2806" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23816960/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Phase%20III%20study%20of%20afatinib%20or%20cisplatin%20plus%20pemetrexed%20in%20patients%20with%20metastatic%20lung%20adenocarcinoma%20with%20EGFR%20mutations&author=LV%20Sequist&author=JC%20Yang&author=N%20Yamamoto&volume=31&publication_year=2013&pages=3327-3334&pmid=23816960&doi=10.1200/JCO.2012.44.2806&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B12"> <span class="label">12.</span><cite>Solomon BJ Mok T Kim DW, etal: First-line crizotinib versus chemotherapy in ALK-positive lung cancer N Engl J Med 371:2167–2177,2014</cite> [<a href="https://doi.org/10.1056/NEJMoa1408440" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25470694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=First-line%20crizotinib%20versus%20chemotherapy%20in%20ALK-positive%20lung%20cancer&author=BJ%20Solomon&author=T%20Mok&author=DW%20Kim&volume=371&publication_year=2014&pages=2167-2177&pmid=25470694&doi=10.1056/NEJMoa1408440&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B13"> <span class="label">13.</span><cite>Steuer CE, Khuri FR, Ramalingam SS: The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer Cancer 121:E1–E6,2015</cite> [<a href="https://doi.org/10.1002/cncr.29139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25521095/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&title=The%20next%20generation%20of%20epidermal%20growth%20factor%20receptor%20tyrosine%20kinase%20inhibitors%20in%20the%20treatment%20of%20lung%20cancer&author=CE%20Steuer&author=FR%20Khuri&author=SS%20Ramalingam&volume=121&publication_year=2015&pages=E1-E6&pmid=25521095&doi=10.1002/cncr.29139&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B14"> <span class="label">14.</span><cite>Gettinger SN Horn L Gandhi L, etal: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33:2004–2012,2015</cite> [<a href="https://doi.org/10.1200/JCO.2014.58.3708" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4672027/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25897158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Overall%20survival%20and%20long-term%20safety%20of%20nivolumab%20(anti-programmed%20death%201%20antibody,%20BMS-936558,%20ONO-4538)%20in%20patients%20with%20previously%20treated%20advanced%20non-small-cell%20lung%20cancer&author=SN%20Gettinger&author=L%20Horn&author=L%20Gandhi&volume=33&publication_year=2015&pages=2004-2012&pmid=25897158&doi=10.1200/JCO.2014.58.3708&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B15"> <span class="label">15.</span><cite>Larkin J Lao CD Urba WJ, etal: Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials JAMA Oncol 1:433–440,2015</cite> [<a href="https://doi.org/10.1001/jamaoncol.2015.1184" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26181250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol&title=Efficacy%20and%20safety%20of%20nivolumab%20in%20patients%20with%20BRAF%20V600%20mutant%20and%20BRAF%20wild-type%20advanced%20melanoma:%20A%20pooled%20analysis%20of%204%20clinical%20trials&author=J%20Larkin&author=CD%20Lao&author=WJ%20Urba&volume=1&publication_year=2015&pages=433-440&pmid=26181250&doi=10.1001/jamaoncol.2015.1184&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B16"> <span class="label">16.</span><cite>Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12:252–264,2012</cite> [<a href="https://doi.org/10.1038/nrc3239" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4856023/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22437870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer&title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&author=DM%20Pardoll&volume=12&publication_year=2012&pages=252-264&pmid=22437870&doi=10.1038/nrc3239&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B17"> <span class="label">17.</span><cite>Schadendorf D Hodi FS Robert C, etal: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J Clin Oncol 33:1889–1894,2015</cite> [<a href="https://doi.org/10.1200/JCO.2014.56.2736" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5089162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25667295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Pooled%20analysis%20of%20long-term%20survival%20data%20from%20phase%20II%20and%20phase%20III%20trials%20of%20ipilimumab%20in%20unresectable%20or%20metastatic%20melanoma&author=D%20Schadendorf&author=FS%20Hodi&author=C%20Robert&volume=33&publication_year=2015&pages=1889-1894&pmid=25667295&doi=10.1200/JCO.2014.56.2736&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B18"> <span class="label">18.</span><cite>Topalian SL Sznol M McDermott DF, etal: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32:1020–1030,2014</cite> [<a href="https://doi.org/10.1200/JCO.2013.53.0105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4811023/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24590637/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Survival,%20durable%20tumor%20remission,%20and%20long-term%20safety%20in%20patients%20with%20advanced%20melanoma%20receiving%20nivolumab&author=SL%20Topalian&author=M%20Sznol&author=DF%20McDermott&volume=32&publication_year=2014&pages=1020-1030&pmid=24590637&doi=10.1200/JCO.2013.53.0105&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B19"> <span class="label">19.</span><cite>Brahmer JR Drake CG Wollner I, etal: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28:3167–3175,2010</cite> [<a href="https://doi.org/10.1200/JCO.2009.26.7609" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4834717/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20516446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol&title=Phase%20I%20study%20of%20single-agent%20anti-programmed%20death-1%20(MDX-1106)%20in%20refractory%20solid%20tumors:%20Safety,%20clinical%20activity,%20pharmacodynamics,%20and%20immunologic%20correlates&author=JR%20Brahmer&author=CG%20Drake&author=I%20Wollner&volume=28&publication_year=2010&pages=3167-3175&pmid=20516446&doi=10.1200/JCO.2009.26.7609&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B20"> <span class="label">20.</span><cite>Wang C Thudium KB Han M, etal: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates Cancer Immunol Res 2:846–856,2014</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-14-0040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24872026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Immunol%20Res&title=In%20vitro%20characterization%20of%20the%20anti-PD-1%20antibody%20nivolumab,%20BMS-936558,%20and%20in%20vivo%20toxicology%20in%20non-human%20primates&author=C%20Wang&author=KB%20Thudium&author=M%20Han&volume=2&publication_year=2014&pages=846-856&pmid=24872026&doi=10.1158/2326-6066.CIR-14-0040&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B21"> <span class="label">21.</span><cite>Brahmer J Reckamp KL Baas P, etal: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373:123–135,2015</cite> [<a href="https://doi.org/10.1056/NEJMoa1504627" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4681400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26028407/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20squamous-cell%20non-small-cell%20lung%20cancer&author=J%20Brahmer&author=KL%20Reckamp&author=P%20Baas&volume=373&publication_year=2015&pages=123-135&pmid=26028407&doi=10.1056/NEJMoa1504627&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B22"> <span class="label">22.</span><cite>Borghaei H Paz-Ares L Horn L, etal: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373:1627–1639,2015</cite> [<a href="https://doi.org/10.1056/NEJMoa1507643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5705936/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20nonsquamous%20non-small-cell%20lung%20cancer&author=H%20Borghaei&author=L%20Paz-Ares&author=L%20Horn&volume=373&publication_year=2015&pages=1627-1639&pmid=26412456&doi=10.1056/NEJMoa1507643&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B23"> <span class="label">23.</span><cite> OPDIVO (nivolumab) [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, October 2015.</cite> </li> <li id="B24"> <span class="label">24.</span><cite> European public assessment report (EPAR) for nivolumab BMS product information: Summary of product characteristics. <a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf</a>.</cite> </li> <li id="B25"> <span class="label">25.</span><cite>Eisenhauer EA Therasse P Bogaerts J, etal: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45:228–247,2009</cite> [<a href="https://doi.org/10.1016/j.ejca.2008.10.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer&title=New%20response%20evaluation%20criteria%20in%20solid%20tumours:%20Revised%20RECIST%20guideline%20(version%201.1)&author=EA%20Eisenhauer&author=P%20Therasse&author=J%20Bogaerts&volume=45&publication_year=2009&pages=228-247&pmid=19097774&doi=10.1016/j.ejca.2008.10.026&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B26"> <span class="label">26.</span><cite> Goldstraw P (ed): International Association for the Study of Lung Cancer: Staging Manual in Thoracic Oncology. Orange Park, FL, Editorial Rx Press, 2009.</cite> [<a href="https://scholar.google.com/scholar_lookup?Goldstraw%20P%20(ed):%20International%20Association%20for%20the%20Study%20of%20Lung%20Cancer:%20Staging%20Manual%20in%20Thoracic%20Oncology.%20Orange%20Park,%20FL,%20Editorial%20Rx%20Press,%202009." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B27"> <span class="label">27.</span><cite> National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. NIH publication 09-7473. May 29, 2009 (v.4.03: June 14, 2010). <a href="http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf</a>.</cite> </li> <li id="B28"> <span class="label">28.</span><cite>Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26:404–413,1934</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Biometrika&title=The%20use%20of%20confidence%20or%20fiducial%20limits%20illustrated%20in%20the%20case%20of%20the%20binomial&author=CJ%20Clopper&author=ES%20Pearson&volume=26&publication_year=1934&pages=404-413&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B29"> <span class="label">29.</span><cite> Greenwood M.: The natural duration of cancer. Reports on Public Health and Medical Subjects. 33:1-26. London, United Kingdom, HM Stationery Office, 1926.</cite> [<a href="https://scholar.google.com/scholar_lookup?Greenwood%20M.:%20The%20natural%20duration%20of%20cancer.%20Reports%20on%20Public%20Health%20and%20Medical%20Subjects.%2033:1-26.%20London,%20United%20Kingdom,%20HM%20Stationery%20Office,%201926." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B30"> <span class="label">30.</span><cite>Rizvi NA Mazières J Planchard D, etal: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial Lancet Oncol 16:257–265,2015</cite> [<a href="https://doi.org/10.1016/S1470-2045(15)70054-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5726228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25704439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol&title=Activity%20and%20safety%20of%20nivolumab,%20an%20anti-PD-1%20immune%20checkpoint%20inhibitor,%20for%20patients%20with%20advanced,%20refractory%20squamous%20non-small-cell%20lung%20cancer%20(CheckMate%20063):%20A%20phase%202,%20single-arm%20trial&author=NA%20Rizvi&author=J%20Mazi%C3%A8res&author=D%20Planchard&volume=16&publication_year=2015&pages=257-265&pmid=25704439&doi=10.1016/S1470-2045(15)70054-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B31"> <span class="label">31.</span><cite> KEYTRUDA (pembrolizumab) [package insert]. Whitehouse Station, NJ, Merck Sharp & Dohme, a subsidiary of Merck, October 2015.</cite> </li> <li id="B32"> <span class="label">32.</span><cite>Champiat S Ferté C Lebel-Binay S, etal: Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy OncoImmunology 3:e27817,2014</cite> [<a href="https://doi.org/10.4161/onci.27817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3937193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24605269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=OncoImmunology&title=Exomics%20and%20immunogenics:%20Bridging%20mutational%20load%20and%20immune%20checkpoints%20efficacy&author=S%20Champiat&author=C%20Fert%C3%A9&author=S%20Lebel-Binay&volume=3&publication_year=2014&pages=e27817&pmid=24605269&doi=10.4161/onci.27817&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="B33"> <span class="label">33.</span><cite>Rizvi NA Hellmann MD Snyder A, etal: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348:124–128,2015</cite> [<a href="https://doi.org/10.1126/science.aaa1348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4993154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25765070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&title=Cancer%20immunology.%20Mutational%20landscape%20determines%20sensitivity%20to%20PD-1%20blockade%20in%20non-small%20cell%20lung%20cancer&author=NA%20Rizvi&author=MD%20Hellmann&author=A%20Snyder&volume=348&publication_year=2015&pages=124-128&pmid=25765070&doi=10.1126/science.aaa1348&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> </ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless"> <p>Articles from Journal of Clinical Oncology are provided here courtesy of <strong>American Society of Clinical Oncology</strong></p></footer></section></article> </main> </div> </div> </div>  <div class="pmc-sidenav desktop:grid-col-4 display-flex"> <section class="pmc-sidenav__container" aria-label="Article resources and navigation"> <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled"> <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" /> </button> <div class="display-none desktop:display-block"> <section class="margin-top-4 desktop:margin-top-0"> <h2 class="margin-top-0">ACTIONS</h2> <ul class="usa-list usa-list--unstyled usa-list--actions"> <li> <a href="https://doi.org/10.1200/JCO.2016.66.9929" class="usa-button usa-button--outline width-24 font-xs usa-link--external padding-left-0 padding-right-0" target="_blank" rel="noreferrer noopener" data-ga-category="actions" data-ga-action="click" data-ga-label="publisher_link_desktop" > <span class="height-3 display-inline-flex flex-align-center">View on publisher site</span> </a> </li> <li> <a href="pdf/JCO.2016.66.9929.pdf" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">PDF (728.9 KB)</span> </a> </li> <li> <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_desktop" data-all-citations-url="/resources/citations/5569692/" data-citation-style="nlm" data-download-format-link="/resources/citations/5569692/export/" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span> </button> </li> <li> <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_desktop" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC5569692%2F%23open-collections-dialog" data-in-collections="false"> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">Collections</span> </button> </li> <li class="pmc-permalink"> <button type="button" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC5569692/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC5569692/"> <h2 class="margin-top-0">RESOURCES</h2> <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-similar-articles" data-ga-category="resources_accordion" data-ga-action="open_similar_articles" data-ga-label="/articles/PMC5569692/" data-action-open="open_similar_articles" data-action-close="close_similar_articles" > Similar articles </button> </h3> <div id="resources-similar-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/similar-article-links/27354485/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-cited-by-other-articles" data-ga-category="resources_accordion" data-ga-action="open_cited_by" data-ga-label="/articles/PMC5569692/" data-action-open="open_cited_by" data-action-close="close_cited_by" > Cited by other articles </button> </h3> <div id="resources-cited-by-other-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/cited-by-links/27354485/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-links-to-ncbi-databases" data-ga-category="resources_accordion" data-ga-action="open_NCBI_links" data-ga-label="/articles/PMC5569692/" data-action-open="open_NCBI_links" data-action-close="close_NCBI_link" > Links to NCBI Databases </button> </h3> <div id="resources-links-to-ncbi-databases" class="usa-accordion__content usa-prose" data-source-url="/resources/db-links/5569692/" > </div> </div> </section> <section class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4" data-title-text="On this page" data-title-heading-level="h2" data-scroll-offset="0" data-root-margin="-10% 0px -80% 0px" data-main-content-selector="main" data-threshold="1" hidden ></section> </section> </div> <div class="overlay" role="dialog" aria-label="Citation Dialog" hidden> <div class="dialog citation-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Cite</h2> <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto" tabindex="1"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="citation-text-block"> <div class="citation-text margin-bottom-2"></div> <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center"> <li> <button class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus" data-ga-category="save_share" data-ga-action="cite" data-ga-label="copy" tabindex="2"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span>Copy</span> </button> </li> <li> <a href="#" role="button" class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button" data-ga-category="save_share" data-ga-action="cite" data-ga-label="download" title="Download a file for external citation management software" tabindex="3"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-none mobile-lg:display-inline">Download .nbib</span> <span class="display-inline mobile-lg:display-none">.nbib</span> </a> </li> <li> <div class="display-inline-flex flex-align-center"> <label class="usa-label margin-top-0">Format:</label> <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" > <option data-style-url-name="ama" value="AMA" > AMA </option> <option data-style-url-name="apa" value="APA" > APA </option> <option data-style-url-name="mla" value="MLA" > MLA </option> <option data-style-url-name="nlm" value="NLM" selected="selected"> NLM </option> </select> </div> </li> </ul> </div> </div> </div> <div class="overlay" role="dialog" hidden> <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Add to Collections</h2> </div> <div class="collections-action-panel action-panel"> <form id="collections-action-dialog-form" class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors" data-existing-collections-url="/list-existing-collections/" data-add-to-existing-collection-url="/add-to-existing-collection/" data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/" data-myncbi-max-collection-name-length="100" data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"> <input type="hidden" name="csrfmiddlewaretoken" value="zGJe7mbE7r6BavVEgUNGpjUGiVr0N0F6WnnwDWJePTYktgHEE30gvUQe1KmglZKQ"> <fieldset class="usa-fieldset margin-bottom-2"> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-new" class="usa-radio__input usa-radio__input--tile collections-new margin-top-0" name="collections" value="new" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_new" /> <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label> </div> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-existing" class="usa-radio__input usa-radio__input--tile collections-existing" name="collections" value="existing" checked="true" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_existing" /> <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label> </div> </fieldset> <fieldset class="usa-fieldset margin-bottom-2"> <div class="action-panel-control-wrap new-collections-controls"> <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0"> Name your collection <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr> </label> <input type="text" name="add-to-new-collection" id="collections-action-dialog-add-to-new" class="usa-input collections-action-add-to-new" pattern="[^"&=<>/]*" title="The following characters are not allowed in the Name field: "&=<>/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection" required /> </div> <div class="action-panel-control-wrap existing-collections-controls"> <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0"> Choose a collection </label> <select id="collections-action-dialog-add-to-existing" class="usa-select collections-action-add-to-existing" data-ga-category="collections_button" data-ga-action="select_collection" data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'"> </select> <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message"> Unable to load your collection due to an error<br> <a href="#">Please try again</a> </div> </div> </fieldset> <div class="display-inline-flex"> <button class="usa-button margin-top-0 action-panel-submit" type="submit" data-loading-label="Adding..." data-pinger-ignore data-ga-category="collections_button" data-ga-action="click" data-ga-label="add"> Add </button> <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel" aria-label="Close 'Add to Collections' panel" ref="linksrc=close_collections_panel" data-ga-category="collections_button" data-ga-action="click" data-ga-label="cancel"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class="ncbi-footer ncbi-dark-background " > <div class="ncbi-footer__icon-section"> <div class="ncbi-footer__social-header"> Follow NCBI </div> <div class="grid-container ncbi-footer__ncbi-social-icons-container"> <a href="https://twitter.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="40" height="40" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span> </a> <a href="https://www.facebook.com/ncbi.nlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="16" height="29" focusable="false" aria-hidden="true" viewBox="0 0 16 29" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z"> </path> </svg> <span class="usa-sr-only">NCBI on Facebook</span> </a> <a href="https://www.linkedin.com/company/ncbinlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="25" height="23" viewBox="0 0 26 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z"> </path> <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z"> </path> <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z"> </path> </svg> <span class="usa-sr-only">NCBI on LinkedIn</span> </a> <a href="https://github.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="28" height="27" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z"> </path> </svg> <span class="usa-sr-only">NCBI on GitHub</span> </a> <a href="https://ncbiinsights.ncbi.nlm.nih.gov/" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="26" height="26" viewBox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z"> </path> <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z"> </path> <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z"> </path> </svg> <span class="usa-sr-only">NCBI RSS feed</span> </a> </div> </div> <div data-testid="gridContainer" class="grid-container ncbi-footer__container"> <div class="grid-row ncbi-footer__main-content-container" data-testid="grid"> <div class="ncbi-footer__column"> <p class="ncbi-footer__circled-icons-heading"> Connect with NLM </p> <div class="ncbi-footer__circled-icons-list"> <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="32" height="32" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span> </a> <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="13" height="24" viewBox="0 0 13 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z"> </path> </svg> <span class="usa-sr-only">NLM on Facebook</span> </a> <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="21" height="15" viewBox="0 0 21 15" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z" fill="white" /> </svg> <span class="usa-sr-only">NLM on YouTube</span> </a> </div> </div> <address class="ncbi-footer__address ncbi-footer__column"> <p> <a class="usa-link usa-link--external" href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323" rel="noopener noreferrer" target="_blank">National Library of Medicine <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a> </p> </address> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link usa-link--alt ncbi-footer__link" > Web Policies </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link usa-link--alt ncbi-footer__link" > FOIA </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS Vulnerability Disclosure </a> </li> </ul> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://support.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > Help </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link usa-link--alt ncbi-footer__link" > Accessibility </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link usa-link--alt ncbi-footer__link" > Careers </a> </li> </ul> </div> <div class="grid-row grid-col-12" data-testid="grid"> <ul class="ncbi-footer__bottom-links-list"> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NLM </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NIH </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > USA.gov </a> </li> </ul> </div> </div> </footer> <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script> <button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top"> <label>Back to Top</label> <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#arrow_upward"></use> </svg> </button> <script src="https://code.jquery.com/jquery-3.5.0.min.js" integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ=" crossorigin="anonymous"> </script> <script type="text/javascript">var exports = {};</script> <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script> <script type="application/javascript"> window.ncbi = window.ncbi || {}; window.ncbi.pmc = window.ncbi.pmc || {}; window.ncbi.pmc.options = { logLevel: 'INFO', staticEndpoint: '/static/', citeCookieName: 'pmc-cf', }; </script> <script type="module" crossorigin="" src="/static/assets/base-9bea7450.js"></script> <script type="module" crossorigin="" src="/static/assets/article-722d91a2.js"></script> </body> </html>

CINXE.COM

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer - PMC